[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 20967
1. Deeg DJH, Thomése GCF: Discrepancies between personal income and neighbourhood status: effects on physical and mental health. Eur J Ageing; 2005 Jun;2(2):98-108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using baseline data from the Longitudinal Aging Study Amsterdam, 2,540 non-institutionalised persons aged 55-85 years were classified based on self-reported income and neighbourhood status.
  • Both categories were compared with the same reference category: matched-high (MH, high personal and high neighbourhood income status).
  • The data show discrepant income effects (DL vs. MH) on physical and cognitive ability, self-rated health, and loneliness, and discrepant neighbourhood effects (DH vs. MH) on physical and cognitive ability, depressive symptoms, and loneliness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Epidemiol. 2003 Oct;13(9):620-8 [14732301.001]
  • [Cites] Psychol Aging. 1996 Jun;11(2):342-52 [8795063.001]
  • [Cites] Am J Public Health. 2004 Oct;94(10 ):1768-74 [15451748.001]
  • [Cites] J Epidemiol Community Health. 2000 May;54(5):367-74 [10814658.001]
  • [Cites] Soc Sci Med. 2004 Dec;59(11):2271-84 [15450703.001]
  • [Cites] Health Place. 2003 Sep;9(3):263-71 [12810333.001]
  • [Cites] J Clin Epidemiol. 2002 Apr;55(4):319-28 [11927198.001]
  • [Cites] Tijdschr Gerontol Geriatr. 2001 Aug;32(4):146-9 [11565417.001]
  • [Cites] Maandstat Bevolking. 1992 Jul;40(7):14-27 [12285285.001]
  • [Cites] Psychol Med. 1997 Jan;27(1):231-5 [9122304.001]
  • [Cites] Soc Sci Med. 2004 Dec;59(12):2409-19 [15474197.001]
  • [Cites] Soc Sci Med. 2005 Apr;60(7):1557-69 [15652687.001]
  • [Cites] Am J Epidemiol. 2002 Mar 15;155(6):507-15 [11882524.001]
  • [Cites] J Aging Phys Act. 2004 Jan;12(1):45-63 [15211020.001]
  • [Cites] J Epidemiol Community Health. 1997 Dec;51(6):676-85 [9519132.001]
  • [Cites] BMJ. 2001 May 19;322(7296):1233-6 [11358781.001]
  • [Cites] J Gerontol. 1994 Mar;49(2):M85-94 [8126356.001]
  • [Cites] BMJ. 1997 Apr 5;314(7086):1037-40 [9112854.001]
  • [Cites] Am J Epidemiol. 1997 Sep 1;146(5):418-28 [9290502.001]
  • [Cites] J Epidemiol Community Health. 2001 Dec;55(12 ):895-904 [11707484.001]
  • [Cites] Soc Sci Med. 2002 Jul;55(1):21-31 [12137186.001]
  • [Cites] J Epidemiol Community Health. 2004 Apr;58(4):333-9 [15026450.001]
  • [Cites] Soc Sci Med. 2002 Jul;55(1):125-39 [12137182.001]
  • [Cites] Gerontologist. 1995 Aug;35(4):541-8 [7557525.001]
  • [Cites] Soc Sci Med. 2003 Sep;57(5):861-73 [12850111.001]
  • (PMID = 28794722.001).
  • [ISSN] 1613-9372
  • [Journal-full-title] European journal of ageing
  • [ISO-abbreviation] Eur J Ageing
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Income / Mental health / Neighbourhood / Perceptions / Physical health
  •  go-up   go-down


2. Díez L, Guijarro IG, Vaamonde P, Fernández P: [Primary manifestation of Hodgkin lymphoma in adenoid. About a case]. Acta Otorrinolaringol Esp; 2010 Nov-Dec;61(6):462-4
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary manifestation of Hodgkin lymphoma in adenoid. About a case].
  • [Transliterated title] Manifestación primaria de linfoma de Hodgkin en adenoides. A propósito de un caso.
  • Lymphomas are the second leading cause of malignancy in head and neck.
  • Hodgkin's disease (HD) accounts for only 10-35% of all cases, where the lymph node is affected in 70-80%.
  • We present the case of a patient with HD with extranodal involvement, given the rarity of this entity.
  • [MeSH-major] Adenoids. Hodgkin Disease / diagnosis. Pharyngeal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Adenoids.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 20092806.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Liu TY, Wu SJ, Huang MH, Lo FY, Tsai MH, Tsai CH, Hsu SM, Lin CW: EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. Mol Cancer; 2010;9:32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis.
  • BACKGROUND: About 30-50% of Hodgkin lymphomas (HLs) harbor the Epstein-Barr virus (EBV), but the impact of EBV infection on clinical outcomes has been unclear.
  • RESULTS: EBER1 was transfected into two HL cell lines, KMH2 and L428, and microarrays were used to screen for EBER1-induced changes.
  • We found that EBER1 suppressed p21cip1/waf1 transcription in HL cell lines.
  • Suppression of p21cip1/waf1 in the EBER1+ HL cell lines was associated with increased resistance to histone deacetylase inhibitors or proteasome inhibitors, drugs known to cause apoptosis by increasing p21cip1/waf1 levels.
  • On biopsy specimens, EBV+ HLs had weaker expression of both p21cip1/waf1 and active caspase 3.
  • Clinically, suppression of p21cip1/waf1 in EBV+ HLs was associated with a worse 2-year disease-free survival rate (45% for EBV+ HLs vs. 77% for EBV- HLs, p = 0.002).
  • The anti-apoptotic activity of EBER1 may be important in the rescue of Reed-Sternberg cells from drug-induced apoptosis and in the clinical behaviors of EBV+ HLs.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Herpesvirus 4, Human / physiology. Hodgkin Disease / diagnosis. Hodgkin Disease / virology
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cyclin D2 / metabolism. Drug Resistance, Neoplasm / drug effects. Early Growth Response Protein 1 / genetics. Early Growth Response Protein 1 / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. Hydroxamic Acids / pharmacology. Leupeptins / pharmacology. Models, Biological. Prognosis. RNA, Viral / metabolism. STAT1 Transcription Factor / genetics. STAT1 Transcription Factor / metabolism. Transcription, Genetic / drug effects. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Dec 15;19(24):6742-50 [11118209.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3815-21 [19470931.001]
  • [Cites] EMBO J. 2002 Mar 1;21(5):954-65 [11867523.001]
  • [Cites] Blood. 2002 Jul 1;100(1):36-42 [12070005.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1540-1 [12424128.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):639-49 [12479224.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):238-47 [11091847.001]
  • [Cites] J Virol. 2003 Jan;77(2):1481-500 [12502863.001]
  • [Cites] Cell. 2003 Oct 3;115(1):71-82 [14532004.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7181-91 [14562046.001]
  • [Cites] Eur J Biochem. 2004 May;271(10):1895-905 [15128299.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5332-7 [15289339.001]
  • [Cites] J Virol. 2004 Nov;78(21):11487-505 [15479791.001]
  • [Cites] Leukemia. 1988 Jun;2(6):371-6 [3131596.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1169-74 [8118801.001]
  • [Cites] Science. 1996 May 3;272(5262):719-22 [8614832.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2748-59 [8654372.001]
  • [Cites] Annu Rev Med. 1999;50:401-23 [10073286.001]
  • [Cites] Pathol Int. 1999 Jun;49(6):506-12 [10469393.001]
  • [Cites] J Cell Biochem. 2005 Jan 1;94(1):153-67 [15523672.001]
  • [Cites] Rev Med Virol. 2005 Jan-Feb;15(1):3-15 [15386591.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3980-5 [15899785.001]
  • [Cites] Curr Opin Cell Biol. 2005 Jun;17(3):302-8 [15901501.001]
  • [Cites] Nat Rev Microbiol. 2005 Oct;3(10):799-808 [16175175.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] J Virol. 2005 Dec;79(23):14562-9 [16282456.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1731-2 [16461762.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1812-5 [16261158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14935-40 [17001014.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1932-40 [17065008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17337-42 [17085592.001]
  • [Cites] Drug Resist Updat. 2007 Feb-Apr;10(1-2):13-29 [17303468.001]
  • [Cites] Nucleic Acids Res. 2007;35(8):2503-12 [17395637.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3380-7 [17545546.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1367-74 [17412634.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):890-900 [17889663.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]
  • [Cites] Annu Rev Pathol. 2006;1:375-404 [18039120.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1448-55 [18006702.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1369-77 [18316600.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 May;9(5):402-12 [18431400.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):321-6 [18484093.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1424-33 [18541724.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1285-94 [11850848.001]
  • (PMID = 20144199.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin D2; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Epstein-Barr virus encoded RNA 1; 0 / Hydroxamic Acids; 0 / Leupeptins; 0 / RNA, Viral; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 0 / Tumor Suppressor Protein p53; 0 / carbobenzoxy-leucyl-leucyl-norvalinal; 3X2S926L3Z / trichostatin A
  • [Other-IDs] NLM/ PMC2834611
  •  go-up   go-down


Advertisement
4. Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, Montserrat E, Monzo M: MicroRNA expression profiling in classic Hodgkin lymphoma. Blood; 2008 Mar 1;111(5):2825-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression profiling in classic Hodgkin lymphoma.
  • We analyzed miRNA expression in classic Hodgkin lymphoma (cHL) and the influence of Epstein-Barr virus (EBV) infection on the miRNA expression profiles.
  • The expression of 157 miRNAs in lymph nodes from 49 cHL patients and 10 reactive lymph nodes (RLNs) was analyzed by real-time polymerase chain reaction (PCR).
  • Hierarchic clustering revealed 3 well-defined groups: nodular sclerosis cHL, mixed cellularity cHL, and RLNs.
  • A distinctive signature of 25 miRNAs differentiated cHL from RLNs, and 36 miRNAs were differentially expressed in the nodular sclerosis and mixed cellularity subtypes.
  • These results were validated in a set of 30 cHLs and 5 RLNs, and in 3 cHL cell lines. miR-96, miR-128a, and miR-128b were selectively down-regulated in cHL with EBV.
  • Our findings suggest that miRNAs play an important role in the biology of cHL and may be useful in developing therapies targeting miRNAs.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Herpesvirus 4, Human / physiology. Humans. In Situ Hybridization. Lymph Nodes / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089852.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


5. Massini G, Siemer D, Hohaus S: EBV in Hodgkin Lymphoma. Mediterr J Hematol Infect Dis; 2009;1(2):e2009013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV in Hodgkin Lymphoma.
  • Up to 40% of Hodgkin lymphoma (HL) cases are associated with the Epstein-Barr virus (EBV).
  • Clonal viral genomes can be found in the HL tumor cells, the Hodgkin Reed-Sternberg cells (HRS).
  • The presence of EBV in HL is associated with several clinicopathological characteristics: It is more frequent in cases with mixed cellular histology, in males, in children and older adults, and in developing countries, while the young-adult onset HL of nodular sclerosis type in industrialized countries is typically EBV-negative.
  • Recent studies suggest a genetic predisposition to develop EBV-associated HL.
  • Circulating EBV-DNA may serve as a biomarker to monitor response to therapy, and eventually, EBV will become a target for therapeutic intervention also in HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Dec 15;106(13):4345-50 [16131568.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):460-4 [16428487.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1650-5 [16983344.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11668-76 [17178861.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Lett. 2008 Oct 18;270(1):66-76 [18539384.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1499-507 [18646185.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):537-48 [19017178.001]
  • [Cites] J Infect Dis. 1979 May;139(5):553-8 [220340.001]
  • [Cites] Nature. 1989 Dec 21-28;342(6252):929-31 [2594086.001]
  • [Cites] J Infect Dis. 1971 Mar;123(3):263-70 [4329526.001]
  • [Cites] J Infect Dis. 1973 Apr;127(4):471-3 [4348499.001]
  • [Cites] Wistar Inst Symp Monogr. 1965 Sep;4:69-82 [5884338.001]
  • [Cites] Arch Virol. 1998;143(4):803-13 [9638150.001]
  • [Cites] J Med Virol. 1999 Apr;57(4):383-9 [10089051.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] J Pathol. 1999 Feb;187(3):326-30 [10398087.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4249-52 [16123211.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):463-8 [16534596.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;310:61-80 [16909907.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1376-81 [17496310.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5771-8 [17575144.001]
  • [Cites] J Virol. 2007 Sep;81(18):10092-100 [17626071.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3310-5 [17630352.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1470-4 [18024394.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1342-9 [18042690.001]
  • [Cites] J Immunol. 2007 Dec 15;179(12):8225-34 [18056366.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):716-9 [18470916.001]
  • [Cites] Virology. 1991 Apr;181(2):595-608 [1849678.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):279-92 [18556771.001]
  • [Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1769-77 [18661399.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6974-8 [18980992.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1352-6 [19201467.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):976-86 [19223558.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):981-9 [19380639.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):158-64 [19429479.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3815-21 [19470931.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):751-8 [8657279.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] J Virol. 1997 Jul;71(7):4882-91 [9188550.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1664-72 [9269787.001]
  • [Cites] J Pathol. 1997 Jul;182(3):299-306 [9349232.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6959-64 [10602470.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1522-8 [10995808.001]
  • [Cites] Immunity. 2000 Oct;13(4):485-95 [11070167.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1579-87 [11301409.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1227-34 [11336475.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3964-73 [11359904.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):239-46 [11091207.001]
  • [Cites] Curr Oncol Rep. 2000 Mar;2(2):199-204 [11122844.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):360-7 [11555713.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1853-7 [11576839.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):282-90 [12562657.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):159-65 [14530808.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]
  • [Cites] Blood. 2002 Apr 15;99(8):3060-2 [11929801.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:23-9 [12078898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] Nat Med. 2003 Mar;9(3):307-14 [12592401.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):442-8 [10404101.001]
  • [Cites] J Virol. 2000 Nov;74(22):10468-79 [11044091.001]
  • [Cites] J Pathol. 2003 Nov;201(3):413-20 [14595753.001]
  • [Cites] J Clin Pathol. 2003 Nov;56(11):811-6 [14600123.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):331-6 [15242681.001]
  • [Cites] J Pathol. 2005 May;206(1):68-75 [15751051.001]
  • [Cites] Br J Haematol. 2005 May;129(4):511-9 [15877733.001]
  • [Cites] Saudi Med J. 2005 Apr;26(4):571-5 [15900362.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1807-14 [11696441.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1474-7 [11830502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5 [12665622.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Clin Immunol. 2003 Oct;109(1):53-63 [14585276.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1326-9 [17438085.001]
  • [Cites] J Virol. 1995 Jun;69(6):3752-8 [7745723.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1360-6 [7882287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):359-63 [8397160.001]
  • [Cites] Mod Pathol. 1995 Aug;8(6):675-9 [8532705.001]
  • [Cites] Arch Dis Child. 1996 Jan;74(1):27-31 [8660041.001]
  • [Cites] Immunity. 1996 Aug;5(2):173-9 [8769480.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):138-41 [9139832.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Cell. 1979 Jul;17(3):661-71 [225039.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):502-6 [2536894.001]
  • [Cites] J Exp Med. 1988 Dec 1;168(6):2059-75 [2848918.001]
  • [Cites] Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101 [5242134.001]
  • [Cites] Science. 1967 Sep 1;157(3792):1064-5 [6036237.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2447-51 [7919364.001]
  • [Cites] J Virol. 1994 Nov;68(11):7374-85 [7933121.001]
  • [Cites] Blood. 1993 Jan 15;81(2):496-501 [8380728.001]
  • [Cites] Int J Cancer. 1996 Mar 15;65(6):781-4 [8631592.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 [14688409.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1373-81 [15007085.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6611-6 [15096587.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2138-46 [15933052.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4048-56 [15961758.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] J Allergy Clin Immunol. 2005 Aug;116(2):251-61; quiz 262 [16083776.001]
  • (PMID = 21416003.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033177
  •  go-up   go-down


6. Sweetenham JW: Novel therapies for Hodgkin Lymphoma. Ther Adv Hematol; 2010 Feb;1(1):23-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapies for Hodgkin Lymphoma.
  • In recent years, improved understanding of the biology of Hodgkin Lymphoma (HL) has uncovered many potential targets for the treatment of this disease.
  • Clarification of the B-ceLL origin of the Hodgkin Reed Sternberg (HRS) cell and of the complex interactions between the HRS cell and the HL microenvironment have provided new insights into the pathophysiology of HL and identified extracellular and intracellular molecules which are essential for HRS survival.
  • New agents directed at these molecules are now in early phase clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23556069.001).
  • [ISSN] 2040-6207
  • [Journal-full-title] Therapeutic advances in hematology
  • [ISO-abbreviation] Ther Adv Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3573386
  • [Keywords] NOTNLM ; Hodgkin Lymphoma / new agents / targeted therapy
  •  go-up   go-down


7. Cyriac S, Sagar TG, Rajendranath R, Rathnam K: Hypereosinophilia in hodgkin lymphoma. Indian J Hematol Blood Transfus; 2008 Jun;24(2):67-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypereosinophilia in hodgkin lymphoma.
  • The incidence of eosinophilia in Hodgkin lymphoma is approximately 15%.
  • Both peripheral and tissue eosinophilia have been noted in Hodgkin lymphoma.
  • Eosinophils have important role in pathobiology of Hodgkin lymphoma.
  • We present a case who was diagnosed to have Hodgkin lymphoma and hypereosinophilia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 Mar 1;69(5):1248-53 [1739923.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:89-96 [9209649.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1207-13 [10666192.001]
  • (PMID = 23100947.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453044
  • [Keywords] NOTNLM ; Hodgkin lymphoma / Hypereosinophilia
  •  go-up   go-down


8. Yuasa T, Rivas-Carrillo JD, Navarro-Alvarez N, Soto-Gutierrez A, Kubota Y, Tabata Y, Okitsu T, Noguchi H, Matsumoto S, Nakaji S, Tanaka N, Kobayashi N: Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2. Cell Transplant; 2009 May/Jun;18(5-6):683-688

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of a bioartificial pancreas (BAP) with immunoisolating fashion has been gaining attention as a new method for treating diabetes.
  • We have been proceeding with the development of a bag-type BAP that can be easily implanted and that allows for the optional injection or rejection of cells at any time.
  • If fibrosis develops around a BAP device, then the permeability of substances transmitted through a semipermeable membrane will decrease, thereby reducing the reactivity with glucose, so it is necessary for the material of the device to have an excellent histocompatibility.
  • We have created a bag-type device for BAP that is 20 × 20 mm in size and comprises two layers of membranes.
  • The inner membrane consists of PAU-coated HD-PE (nonwoven material processed with polyaminourethan) and it is designed to function as a scaffold for cells.
  • We confirmed in this study that the use of an implantable BAP device and bFGF allowed for a better blood flow around the BAP device.
  • There were only minor instances of fibrosis and inflammation reaction around the BAP, thus indicating the BAP that we are currently developing to have an excellent histocompatibility.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880643.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Bioartificial pancreas / Fibroblast growth factor 2 / Neovascularization
  •  go-up   go-down


9. Borlongan CV, Thanos CG, Skinner SJM, Geaney M, Emerich DF: Transplants of Encapsulated Rat Choroid Plexus Cells Exert Neuroprotection in a Rodent Model of Huntington's Disease. Cell Transplant; 2007 Nov;16(10):987-992
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplants of Encapsulated Rat Choroid Plexus Cells Exert Neuroprotection in a Rodent Model of Huntington's Disease.
  • Three days later, unilateral injections of quinolinic acid (QA; 225 nmol) were made into the ipsilateral striatum to mimic the pathology observed in Huntington's disease (HD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28866919.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Alginate / Choroid plexus / Encapsulation / Huntington's disease / Transplant
  •  go-up   go-down


10. Chawla R, Venkatesh P, Garg SP, Mandal S, Tewari HK: Cytomegalovirus retinitis in a patient with non-Hodgkins lymphoma: A diagnostic dilemma. Eur J Ophthalmol; 2005 Jan - Feb 2005;15(1):153-157

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomegalovirus retinitis in a patient with non-Hodgkins lymphoma: A diagnostic dilemma.
  • PURPOSE: Patients with lymphoma can rarely develop cytomegalovirus (CMV) retinitis.
  • Clinically it is difficult to distinguish from intraocular lymphoma.
  • The authors report a rare case of bilateral CMV retinitis in a patient with non-Hodgkins lymphoma with high CD4+ counts.
  • RESULTS: CMV retinitis was clinically suspected due to the presence of large areas of retinal necrosis and hemorrhages in one eye and a demarcation line with white mottled retina in the other eye.
  • The diagnosis of CMV retinitis was confirmed by polymerase chain reaction performed on vitreous sample.
  • CONCLUSIONS: CMV retinitis can develop in cases of lymphoma despite high CD4+ counts.
  • An early diagnosis can be established by performing PCR on vitreous biopsy. (Eur J Ophthalmol 2005; 15: #-7).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221421.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Wilkes L: Starting out - respecting the wishes of a dying patient made all the difference. Nurs Stand; 2009 Mar 11;23(27):27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Starting out - respecting the wishes of a dying patient made all the difference.
  • : While on acute placement on a haematology unit, I looked after a patient who had non-Hodgkin's lymphoma, lung cancer and a hole in his neck where a tracheostomy had been situated.
  • John had been on the unit for a while and would constantly tell me and other staff members that he wanted to go home.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991330.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Farrington M, Wreghitt TG, Lever AML, Dunnett SB, Rosser AE, Barker RA: Neural Transplantation in Huntington's Disease: The NEST-UK Donor Tissue Microbiological Screening Program and Review of the Literature 1. Cell Transplant; 2006 Apr;15(4):279-294

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neural Transplantation in Huntington's Disease: The NEST-UK Donor Tissue Microbiological Screening Program and Review of the Literature 1.
  • Neural transplantation of human fetal tissue for Huntington's disease (HD) is now entering the clinical arena.
  • In this article we summarize the UK-NEST protocol for the screening of human fetal tissue being grafted to patients with mild to moderate HD.
  • This article therefore presents a comprehensive, logical yet pragmatic screening program that could be employed in any clinical studies that use human fetal tissue for neurotransplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863746.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Brain tissue transplantation / Fetal tissue transplantation / Huntington's disease / Microbiological techniques / Tissue transplantation
  •  go-up   go-down


13. Berker N, Batman C, Ozdamar Y, Eranil S, Aslan O, Zilelioglu O: Long-term outcomes of heavy silicone oil tamponade for complicated retinal detachment. Eur J Ophthalmol; 2007 Sep-Oct;17(1):797-803

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess the long-term success rates and complications of heavy silicone oil tamponade (Oxane HD) in the management of complicated retinal detachment with proliferative vitreoretinopathy (PVR).
  • Vitreoretinal surgery with heavy silicone oil (Oxane HD) tamponade was performed in all patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221523.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Kerr C: Chemoradiotherapy in early-stage Hodgkin's disease. Lancet Oncol; 2007 Dec;8(12):1061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy in early-stage Hodgkin's disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28581424.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Carbone A, Cabras A, Gloghini A: HIV-associated Hodgkins lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity. Int J Biol Markers; 2007 Apr - Jun;22(2):161-163

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Hodgkins lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207144.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Quinaux EM, Baumgaertner I, Khalil A, Louvet C, Buyse ME, de Gramont A, André T: Comparison of l and dl forms of folinic acid in Gercor C96.1 trial (A phase III trial comparing bimonthly LV5FU2 to monthly high-dose 5FU-leucovorin in patients with Dukes' B2 and C colon cancer). J Clin Oncol; 2009 May 20;27(15_suppl):e15004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of l and dl forms of folinic acid in Gercor C96.1 trial (A phase III trial comparing bimonthly LV5FU2 to monthly high-dose 5FU-leucovorin in patients with Dukes' B2 and C colon cancer).
  • 2007 20;25:3732-8), patients were randomized to either monthly 5FU-LV hd (dl LV 200 mg/m<sup>2</sup> or l LV 100 mg/m<sup>2</sup> 15 min iv followed by 5FU 400 mg/m<sup>2</sup> 15 min iv, d1-5 q4 wk) or LV5FU2 (dl LV 200 mg/m<sup>2</sup> or l LV 100 mg/m<sup>2</sup> 2-hour infusion followed by iv bolus 5FU 400 mg/m<sup>2</sup> and 22 hours continuous infusion 600 mg/m<sup>2</sup>, d1 and d2 q 2 wk).
  • There were no statistically significant differences between l and dl forms in term of disease free survival (33.3% vs 32.8% of patients with at least one event in l and dl forms respectively, hazard ratio=1.03, 95% CI=[0.82-1.31], p=0.78).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964361.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Malogolowkin MH, Krailo M, Frazier LA, Olson TA: Study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high-risk germ cell tumors: A Children's Oncology Group report. J Clin Oncol; 2009 May 20;27(15_suppl):10035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high-risk germ cell tumors: A Children's Oncology Group report.
  • : 10035 Background: In the intergroup high-risk germ cell tumors (HR-GCT) study (CCG-8882/POG-9049) patients with extragonadal GCT treated with high-dose cisplatin, etoposide, and bleomycin (HD-PEB) had a 2 year-EFS of 84% versus 74% for those treated with standard PEB (PEB), suggesting that treatment intensification might be beneficial.
  • The goal of this study was to establish the maximum tolerated dose (MTD) and toxicity profile of cyclophosphamide combined with PEB in untreated patients with HR-GCT.
  • METHODS: From July 2004 to August 2007, 19 eligible children and adolescents with stage III/IV extragonadal GCT received cisplatin 20 mg/m<sup>2</sup>/day × 5, etoposide 100 mg/m<sup>2</sup>/d × 5, bleomycin 15 mg/m<sup>2</sup> on d1, and escalating doses of cyclophosphamide (1.2, 1.8 or 2.4 g/m<sup>2</sup>) on d1.
  • DLT was defined as any grade 4 non-hematologic toxicity other than nausea and vomiting, fever and infection, and any non-hematologic grade 3 toxicity which had not reversed (< grade 2) within 28 days of treatment; or hematologic toxicity grade 3 or 4, which despite hematopoietic growth factor support, was not reversible within 28 days of treatment.
  • Fifteen of the 19 patients were removed from protocol therapy after 4 cycles of therapy; 11 were disease-free, 2 electively terminated protocol therapy, 1 patient was lost to follow-up, and 1 had progressive disease (PD).
  • Four patients received 2 more cycles of C-PEB, of these 3 were disease-free and 1 had PD.
  • CONCLUSIONS: The addition of cyclophosphamide to the standard PEB regimen is feasible and well tolerated at all dose levels used on this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962582.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Nabil IN Jr, Allam W, Alaoui K, Errihani H: Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nasopharyngeal non Hodgkin lymphoma: A retrospective investigation of 26 patients.
  • : e19552 Background: Primary nasopharyngeal non-Hodgkin lymphoma (NNHL) was uncommon.
  • In this retrospective study we report our experience dealing with this disease at the National Institute of Oncology.
  • METHODS: We retrospectively analyzed various characteristics of Primary NNHL: patient demographics, clinical and histological diagnosis, disease stage, treatment effects and outcome, in 26 patients treated at our institution between January 2001 and December 2007.
  • The major symptoms at first diagnosis were: nasal obstruction (88.6%), hypoacousia (88.4%), epistaxis (33.3%) and rhinorrhea (15.3%).
  • Clinical examination founded bilateral cervical lymph nodes in 17 cases (65%).
  • Histological analysis showed follicular lymphoma in 7 cases (26.9%), large B-cell lymphoma in 11 cases (42,3%) and T lymphoma in 4 cases ( 15,3%).
  • At the end of total treatment, 18 patients (69.2%) achieved complete response and remained disease free while 4 (15.4%) achieved partial response (>70%) and 4 (15.4%) were progressive (these patients received second line chemotherapy).
  • After 110 months median flow-up, median disease free and overall survival were not reached.
  • CONCLUSIONS: From our study and from the literature, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are similar to that of patients with nodal lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yi J, Kim S, Lee S, Park S, Ko Y, Choi J, Kim W: Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usefulness of PET/CT in initial staging and response evaluation of primary gastric lymphoma.
  • : e19541 Background: Positron emission tomography (PET)/computed tomography (CT) scan has a well-established role in the management of non-Hodgkin's lymphoma (NHL).
  • However, in case of the primary gastric lymphoma, which is the most frequent extranodal NHL, the role of PET/CT scan is still controversial.
  • METHODS: We retrospectively analyzed 42 patients with primary gastric lymphoma who underwent PET/CT scans; 32 patients with diffuse large B-cell lymphoma (DLBCL) and 10 patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) were analyzed.
  • After corresponding treatment, response was evaluated by conventional CT scans or PET/CT scans and endoscopy with biopsy Results: Nine patients were up-staged based on the results of their PET/CT scan compared to CT (7 DLBCL, 2 MALT lymphomas) while six patients were down-staged by the PET/CT scan.
  • Three patients with DLBCL, who showed an initially high SUVmax, died of disease progression.
  • All of these gastric lesions were grossly and pathologically benign lesions without evidence of lymphoma cells.
  • CONCLUSIONS: PET/CT scan can help staging patients with primary gastric lymphoma, and the maximum SUV has possibility to have prognostic value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Czuczman MS, Vose J, Zinzani P, Reeder C, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Ervin-Haynes A, Witzig T: Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). J Clin Oncol; 2009 May 20;27(15_suppl):e19504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003).
  • : e19504 Background: Patients with diffuse large-B-cell lymphoma (DLBCL) who are not cured with R-CHOP or high-dose chemotherapy with autologous stem cell rescue have a dismal prognosis.
  • A recent phase II trial (NHL-002) of lenalidomide in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) demonstrated a 19% overall response rate (ORR) with a 7-month median duration of response (DR) in the subset of patients with DLBCL.
  • A supporting international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed or refractory aggressive NHL that had received at least one prior treatment and had measurable disease.
  • METHODS: Patients received 25 mg oral lenalidomide once daily on days 1-21 of every 28-day cycle and continued therapy until disease progression or toxicity.
  • Median time from diagnosis was 2 years (0.4-18.6), patients had received a median of 3 prior treatment regimens (1-10) and 46 of the patients (45%) had received a prior stem cell transplant (DLBCL-stem cell).
  • CONCLUSIONS: This international study demonstrates that lenalidomide is active in heavily pre-treated patients with relapsed or refractory DLBCL and has manageable side effects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Blum KA, Smith M, Fung H, Zalevsky J, Combs D, Ramies DA, Younes A: Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol; 2009 May 20;27(15_suppl):8531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy.
  • : 8531 Background: XmAb2513 is a novel 2<sup>nd</sup>-generation humanized monoclonal antibody (mAb) directed against CD30 (a cell surface antigen expressed on Reed-Sternberg cells of HL and ALCL), with an Fc region engineered to have increased binding affinity to Fcγ receptors (FcγRs) leading to improved FcγR-dependent effector cell functions.
  • In cynomolgus monkeys (cynos), XmAb2513 exposure was dose-proportional with half-lives ranging from 12 - 17d in repeat dose studies, which suggested biweekly (QOW) dosing in man.
  • A Phase 1 study has been initiated to examine the safety and efficacy of XmAb2513 in patients (pts) with relapsed HL and ALCL.
  • METHODS: Phase 1 open-label study with QOW dosing of XmAb2513; dose-escalation study design with doses of 0.3, 1, 3, 6, 9, and 12 mg/kg via IV-infusion to establish the maximum tolerated dose (MTD).
  • RESULTS: 13 HL pts have been enrolled in the 1<sup>st</sup> 4 dose levels (0.3 to 6 mg/kg).
  • 1 pt with an extensive treatment history and chronic immunosuppression died due to fungal pneumonia after a single 3 mg/kg dose.
  • PK parameters were computed for the 1<sup>st</sup> dose alone and for the entire course of XmAb2513 treatment.
  • PK parameters appeared non-linear across the dose range from 0.3 - 3 mg/kg.
  • XmAb2513 has demonstrated encouraging biologic activity in patients with refractory HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960926.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Diehl V, Haverkamp H, Mueller R, Mueller-Hermelink H, Cerny T, Markova J, Ho AD, Kanz L, Greil R, Engert A: Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). J Clin Oncol; 2009 May 20;27(15_suppl):8544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG).
  • : 8544 Background: The GHSG HD9 trial had established BEACOPP escalated (BE) as new standard of care for advanced-stage HL patients.
  • The second question in this trial related to the need of additional radiotherapy (RT) to initial bulk and residual disease.
  • METHODS: HL patients in stage IIB with large mediastinal mass and/or E-lesions or stage III/IV were randomised according to a 2x2-factorial design between: 8BE + RT, 8BE no RT, 4BE+4BB + RT, 4BE+4BB no RT.
  • A total of 156 (9.9%) deaths (72 vs 84) have been observed (22 vs 32 acute or salvage treatment toxicity; 15 vs 24 HL; 22 vs 13 secondary neoplasia).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960959.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Vose JM: Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001. J Clin Oncol; 2009 May 20;27(15_suppl):8560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001.
  • We conducted a phase II trial of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL).
  • Oral lenalidomide 25 mg was self-administered once-daily on days 1-21 of every 28-day cycle for up to 52 weeks as tolerated, or until disease progression.
  • Patients had received a median of 3 prior systemic therapies (1-17) and half of all patients were refractory to their last therapy.
  • Twenty-seven percent (6/22) of patients with follicular lymphoma grade 1 or 2, and 22% (4/18) of patients with small lymphocytic lymphoma responded to therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960983.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Eckardt JR, Ku N, DeMaggio A, Reese M, Levonyak M, Jain V: Impact of direct physician-to-physician contact on accelerating oncology clinical trial accrual. J Clin Oncol; 2009 May 20;27(15_suppl):6613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of direct physician-to-physician contact on accelerating oncology clinical trial accrual.
  • : 6613 Background: The development of more effective oncology agents is critically dependent on the completion of clinical trials; currently, >4000 oncology trials listed in www.clinicaltrials.gov are accruing pts in the US.
  • Unfortunately, only 3-5% of new cancer pts participate in clinical trials and most trials do not meet their projected accrual timelines.
  • Barriers to pt accrual include physician awareness & attitudes, access to protocols, administrative burdens to conduct clinical trials, cost to physicians and pts, and pt concerns about participation in research trials.
  • To overcome at least some of these barriers, we investigated a strategy to improve clinical trial accrual that optimizes trial placement and awareness through a direct physician to physician intervention.
  • METHODS: For each site, a customized enrollment plan is established after initial assessment of interest and accrual potential.
  • Implementation of the enrollment plan includes clinical communications and medical support delivered through direct physician to physician interactions.
  • From Feb 2008 to December 2008, we implemented this strategy to increase accrual to 5 oncology trials (2 placebo controlled randomized trials and 3 phase II trials in breast cancer, non-Hodgkin's lymphoma and soft tissue sarcoma).
  • CONCLUSIONS: The use of our current model of optimizing trial placement and awareness through a direct physician to physician intervention has been successful in significantly accelerating clinical trial accrual in 5/5 trials initiated to date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961766.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Azria D, Gligorov J: Prevalence and management of oropharyngeal candidiasis in cancer patients: Results of a prospective French multicentric survey. J Clin Oncol; 2009 May 20;27(15_suppl):e20590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and management of oropharyngeal candidiasis in cancer patients: Results of a prospective French multicentric survey.
  • International guidelines recommend the use of broad spectrum local antifungal agents as first line treatment using old published data.
  • METHODS: Candidoscope concerned patients suffering from solid tumors or non-Hodgkin's lymphoma (NHL) and still under treatments.
  • Breast cancer population was the most frequent disease presenting untreated OPC (n= 47, 24%).
  • The most common clinical presentation for OPC was the erythematous form (62%).
  • CONCLUSIONS: The prevalence of OPC in treated cancer patients is frequent with important clinical consequences.
  • Systemic treatment compliance delivered according to the international guidelines is often poor and are strongly improved by the use of daily MBT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961172.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Vigil CE, Ayala E, Sokol L: Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e19538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplant in peripheral T cell lymphomas: Single institution 10-year retrospective analysis.
  • : e19538 Background: Peripheral T-cell lymphoma is a rare entitydisease, compromising 10% of non-Hodgkin's lymphoma worldwide and 5% of all lymphoid neoplasms in the United States.
  • High-dose chemotherapy followed by autologous haematopoietic stem cell transplantation, has been explored in recent years with little experiences.
  • METHODS: A retrospective analysis on patients with diagnosis of peripheral T-cell lymphoma receiving autologous stem cell transplant was conducted (January 1997 to July 2008).
  • The patients were stratified according to their International Prognostic Index (IPI), disease status at the time of transplant and histology type.
  • RESULTS: Twenty-nine subjects were identified, with a median age of 51; 13 patients had Anaplastic T cell, 18 patient had PTCL-nos, and 6 patients with angioimmunoblastic T cell lymphoma.
  • Seventeen patients (58.62%) presented with an aa IPI score greater than 2.4 patients were in complete remission, 15 at first relapse, 4 in greater than 1 episode, and 6 with refractory disease at the time of transplantion.Kaplan Meier overall survival (OS) 72 and relapse free survival (RFS) was 62 at 1 year respectively.
  • A multivariate analysis and new risk stratification based on the IPI score system and disease status at time of transplant were employed.
  • CONCLUSIONS: The status at time of transplant with new methods for evaluation of minimal residual disease may help in assessing outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Anastasia A Jr, Mazza R Jr, Giordano L, Balzarotti M Sr, Magagnoli M Sr, Castagna L Sr, Spina M, Michieli M, Tirelli U, Santoro A: Complete response (CR) to ifosfamide, gemcitabine, and vinorelbine (IGEV) and outcome in relapsed/refractory Hodgkin's lymphoma (HL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):8568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response (CR) to ifosfamide, gemcitabine, and vinorelbine (IGEV) and outcome in relapsed/refractory Hodgkin's lymphoma (HL) patients.
  • : 8568 Background: High dose chemotherapy with autologous stem cells transplant (ASCT) is the gold standard in patients with relapsed/refractory HL.
  • METHODS: One hundred twenty one patients with relapsed/refractory HL received 4 courses of IGEV followed by single (N=59) or tandem (N=19) ASCT (Santoro et al., Haematologica 92, 2007).
  • In the univariate analysis favourable factors for outcome were CR vs no-CR to IGEV (PFS: p <0.001, OS: p 0.002), A vs B symptoms (PFS: p 0.003; OS: p 0.05), limited vs advanced stage (PFS: p 0.03; OS: p 0.03), and 1 vs≥2 previous chemotherapy lines (PFS: p 0.03, OS: p 0.02); response to last therapy (relapsed vs refractory) influenced PFS (p 0.03) but not OS (p 0.70).
  • The multivariate analysis confirmed the favourable prognostic role of CR to IGEV (PFS HR: 2.5, CI 95%:1.3; 4.6 - OS HR 2.3, CI 95%:1.1;4.8) and of the number of previous chemotherapy lines (PFS HR:1.8, CI 95%:1.0;3.2 - OS HR 2.1, CI 95%:1.1;3.9).
  • CR to IGEV is the strongest indicator of outcome in relapsed/refractory HL.
  • 2. Achievement of CR to IGEV overcomes the role of initial disease status.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961023.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Fan AC, Orban MW, Shirer AE, Rajwanshi R, Kong C, Natkunam Y, Lee HE, Coutre S, Felsher DW: Nanoscale analysis of changes in signaling proteins in patients treated with single agent atorvastatin for low-grade or refractory NHL. J Clin Oncol; 2009 May 20;27(15_suppl):11011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11011 Background: In preclinical studies using our transgenic lymphoma model, lymphoma regression upon atorvastatin treatment was associated with increased apoptosis and changes in phosphorylation of key signaling pathways including MAPK and STAT.
  • To determine if statins affect tumor signaling in patients, we designed a single arm phase II study, "Atorvastatin in Patients with Low Grade or Refractory Non-Hodgkin's Lymphoma."
  • To characterize changes in protein profiles, we have developed the use of a novel nano-immunoassay system (NIA) to simultaneously measure both phosphorylated and unphosphorylated protein isoforms.
  • Finally, changes in signaling associated with atorvastatin are cell specific: effects on tumor cells were distinct from effects on non-tumor T cells and monocytes.
  • CONCLUSIONS: Single agent atorvastatin has a measurable effect on tumor bioactivity in patients with lymphoma.
  • NIA and multi-color phosphoFACS can be used to monitor changes in cell signaling in very small clinical samples during therapeutic interventions.
  • Determining whether specific signaling molecules may be a biomarker for identifying lymphoma patients that respond to atorvastatin is worthy of further investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963976.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Skarin AT, Vekeman F, Laliberté F, Afonja O, Lafeuille M, Barghout V, Duh MS: Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data. J Clin Oncol; 2009 May 20;27(15_suppl):9624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who had a cancer diagnosis and chemotherapy within 120 days of their first pegfilgrastim injection were identified.
  • Analysis was also stratified by cancer type [Non-Hodgkin's lymphoma (NHL), lung, breast].
  • Further research is being conducted to assess the related clinical and economic impact of this pattern of usage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963900.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Tan H, Tomic K, Daniel G, Hurley D, Barron R: Evaluating risk of hospitalization with G-CSF use in real-world oncology practice. J Clin Oncol; 2009 May 20;27(15_suppl):6626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating risk of hospitalization with G-CSF use in real-world oncology practice.
  • This study examines prophylactic vs. delayed use of G-CSF and compares the effectiveness of prophylaxis with filgrastim (FIL) vs. pegfilgrastim (PEG).
  • METHODS: A retrospective analysis of administrative claims from U.S. commercial health plans identified adult patients with non-Hodgkin's lymphoma, breast, or lung cancer, treated with chemotherapy between July 2004 and January 2008.
  • For these patients, the first course of chemotherapy and each unique cycle with use of G-CSF (FIL or PEG) was identified and designated 'prophylaxis' if used within the first 5 days of each cycle, or 'delayed', if after day 5.
  • A generalized estimating equation (GEE) was used to adjust for baseline demographics and clinical characteristics.
  • Among prophylactic use in real-world oncology practice, PEG was associated with about a two-thirds lower risk of neutropenic hospitalization compared with FIL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961802.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Yoon D, Sohn B, Kim J, Yoo C, Kim S, Lee D, Kim S, Huh J, Lee J, Suh C: The role of prophylactic antimicrobials during autologous stem cell transplantation: A single center experience. J Clin Oncol; 2009 May 20;27(15_suppl):7105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7105 Background: The aim of this retrospective study was to investigate the efficacy of antibiotic prophylaxis during autologous peripheral stem cell transplantation (ASCT) in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961647.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Jeevangi N, Joshi A, Shah M, Kannan S, Gupta S, Nair R, Khattry N: Results of autologous transplants for lymphomas from a tertiary cancer center in India. J Clin Oncol; 2009 May 20;27(15_suppl):7106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of autologous transplants for lymphomas from a tertiary cancer center in India.
  • : 7106 Background: Autologous stem cell transplanation is the standard of care for patients of relapsed and refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL).
  • We report the results of transplants in lymphomas from our center and role of possible prognostic factors.
  • METHODS: All 50 consecutive patients who underwent transplant for HL (70%) and NHL (30%) from August 1994- August 2008 were included in this retrospective study.
  • Fifty eight percent of patients received BEAM (carmustine, etoposide, ara-c and melphalan), 30% LACE (lomustine, ara-c, cyclophosphamide and etoposide), 8% ICE (ifosfamide,carboplatin and etoposide) and 4% high dose melphalan (200mg/m<sup>2</sup>) conditioning regimens.
  • Prognostic factors evaluated for progression free survival (PFS) were serum albumin level and body mass index (BMI) at the time of transplant, stage at diagnosis and source of stem cells, while for over all survival (OS), status of disease at transplant was also included.
  • RESULTS: The median time to transplant was 2.25 years from the time of diagnosis.
  • At the time of transplant, thirty two percent were in complete remission (CR), 50% in partial remission (PR) and 18% had refractory disease (RD).
  • The best disease response rate was 86% (CR+PR) in patients evaluable for response.
  • CONCLUSIONS: These data provide the first published report of outcomes of autologous transplants in lymphomas from India.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Gharib AF, Eltarhony SA, Elsawy WH: Soluble CD44 in patients with aggressive non-Hodgkin's lymphoma: Prognostic and clinical value. J Clin Oncol; 2009 May 20;27(15_suppl):e19539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble CD44 in patients with aggressive non-Hodgkin's lymphoma: Prognostic and clinical value.
  • In this prospective study, we investigated the prognostic and clinical value of s-CD44 in patients with aggressive non-Hodgkin's lymphomas.
  • METHODS: s-CD44 concentration was measured in the sera of 64 patients with aggressive non-Hodgkin's lymphomas treated with standard CHOP by using chemiluminescence-enzyme immunoassay (EIA).
  • RESULTS: Circulating serum CD44 (s-CD44) levels have been found to change in parallel with response to therapy, but little is known about the predictive or prognostic significance of s-CD44.
  • Only 10 (31%) of the 32 patients with an International Prognostic Index (IPI) score 0 or 1 had s-CD44 concentration higher than the median level, whereas 11 (52%) of 21 patients with an IPI score ≥2 had a concentration higher than the median before initiation of treatment (P < .0001).
  • CONCLUSIONS: Our results showed that a high s-CD44 level before treatment is associated with a high IPI score, poor response to treatment, and unfavorable prognosis in aggressive non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Guix B, Bartrina J, Tello J, Quinzanos L, Lacorte T: Dose escalation by high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer: Early results of a prospective comparative trial. J Clin Oncol; 2009 May 20;27(15_suppl):5118

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation by high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer: Early results of a prospective comparative trial.
  • : 5118 Background: To report early and late toxicity and preliminary biochemical outcome in 445 patients with intermediate- or high-risk clinically localized prostate cancer treated with either HD-3D-CRT or with LD-3D-CRT+HDR-B.
  • Pts were assigned to one of the two treatment groups: 76 Gy HD-3D-CRT to the prostate in 38 fractions (group 1; 223 patients) or 46 Gy LD-3D-CRT+ 16 Gy HDR-B given in 2 fractions of 8 Gy (group 2, 222 patients).
  • CONCLUSIONS: High-dose 3D-EBRT +HDR brachytherapy is a safe and effective method of escalating the dose to the prostate without increasing the risk of late effects.
  • Acute and late rectal and urinary complications were significantly reduced with the combined treatment, compared with what was observed with high-dose conventional, 3D-CRT.
  • Short-term PSA control rates tends to be better with in the HDR-boosted patients as spected by higher effective-dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964387.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Sola CB, Silva L, Saliba R, De Lima M, Giralt S, Qazilbash M, Champlin R, Khouri I, Popat U, Hosing C: Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization. J Clin Oncol; 2009 May 20;27(15_suppl):7040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization.
  • : 7040 Background: Patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) who fail to mobilize adequate peripheral blood stem cells (PBSC) often undergo bone marrow (BM) harvest for autologous transplantation.
  • METHODS: In this retrospective study (May 1996-September 2006), we identified 36 out of a total of 750 pts with advanced NHL, who failed to collect adequate PBSC and subsequently underwent BM harvest followed by ABMT.
  • Twelve pts (35%) had history of BM involvement with lymphoma.
  • At the time of stem cell mobilization 18 (50%) were in complete remission (CR), 13 (37%) were in partial remission (PR) and 5 (13%) had progressive disease (PD).
  • RESULTS: The median total nucleated cell dose and CD34+ cell dose harvested/kg were 3.72 x 10<sup>8</sup> (range 0.25-58.0) and 1.6 x 10<sup>6</sup> (range 0.03-5.8), respectively.
  • Causes of death were: disease progression/relapse in 15 (60%), secondary malignancy in 3 (12%), multiorgan failure in 5 (20%), and unknown in 2 (8%).
  • Non-myeloablative allogeneic transplantation may provide better outcomes with similar toxicity and needs to be further studied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Reategui RD, Beltran B, Morales D, Vera L, Quinones P, Portugal K, Desposorio C, Capellino A, Castillo J: AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru.
  • METHODS: The clinical records of 2,502 HIV-infected patients seen in our institution from March 1997 to March 2008 were reviewed.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • From the 48 ARL identified 44 were non Hodgkin lymphoma (NHL) and 4 were Hodgkin lymphoma.
  • From 42 systemic NHL: 38 (90,5%) were of B-cell and 4 (9,5%) were of T-cell.
  • Three groups of patients were included: 13 patients (31%) received HAART previous the diagnosis of ARL, 21 patients (50%) initiated HAART after ARL diagnosis and 8 patients (19%) did not receive HAART.
  • HAART treatment before the diagnosis of NHL increases the survival (54% versus 9,5% versus 25% respectively, p=0.048).
  • This group had a better survival rate than those who did not receive chemotherapy (50% versus 4,5%, p< 0.0001) The overall response to chemotherapy was 80% with CR (n=11, 55%), PR(n=5, 25%) and PD in four (20%).
  • In a multivariate analysis, IPI score > 2, presence of B symptoms and no HAART previous ARL diagnosis were statistically associated to worse survival with p-values of 0.0001, 0.018 and 0.048 respectively.
  • CONCLUSIONS: In our study the use of HAART is effective when started before ARL diagnosis.
  • IPI score > 2, B symptoms and no HAART previous the diagnosis were unfavorable prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Gerrard M, Waxman I, Sposto R, Auperin A, Harrison L, Pinkerton R, Perkins SL, McCarthy K, Raphael M, Patte C, Cairo MS, FAB/LMB 96 Trial: Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial.
  • : 10001 Background: Single pediatric cooperative group studies have demonstrated an EFS ranging from 65 - 75% in C & A with large cell lymphomas arising in the mediastinum (Lones/Cairo et al, J Clin Oncol, 2000; Burkhardt/Reiter et al, Br J Haematol, 2005; Seidman/Reiter et al, J Clin Oncol, 2003).
  • Recently, Staudt and Shipp have independently demonstrated that following gene expression profiling by oligonucleotide microarray that PMBL resembles more like classical Hodgkin lymphoma than diffuse large B-cell lymphoma with enhanced NF-κB pathway gene expression (Rosenwald et al, J Exp Med, 2003; Abramson et al, Blood, 2005).
  • RESULTS: There were 528 patients with stage III/IV disease treated on group B therapy on FAB/LMB 96 resulting in a 2 yr EFS of 84% (CI<sub>95</sub>: 82-86%).
  • 5 yr EFS was significantly inferior compared to the remainder of the other patients with stage III disease treated on group B therapy (54%: CI<sub>95</sub> 38-68% vs 85%: CI<sub>95</sub> 81-88%) (p < 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Zain JM, Foss F, Kelly WK, DeBono J, Petrylak D, Narwal A, Neylon E, Blumenschein G, Lassen U, O'Connor OA: Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8580

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma.
  • A phase I of oral Bel in patients (pts) with solid tumors found a recommended dose for day (d) 1-14, q3w, of 750 mg QD, with option for intra-patient dose escalation if limited toxicity.
  • The current study was initiated to assess if the same dose could be utilized in pts with lymphoma.
  • Pts with relapsed/refractory non-Hodgkin lymphoma (NHL) or Hodgkin's disease (HD) with evaluable disease and acceptable organ functions were eligible.
  • Dose limiting toxicity (DLT) assessed in cycle 1 included: related non-hem grade (gr) 3/4 tox; gr 4 neutropenia > 5 d or with fever > 100.5 °F; gr 4 thrombocytopenia > 7 d.
  • Diagnoses include mantle cell lymphoma (MCL; 4 pts), HD (3 pts), other NHL (2 pts).
  • Non-hem gr 3 events (no gr 4 noted): diarrhea (1 pt each in cohorts A and B, both in cycle 2), fatigue, anorexia, and leg DVT (each in 1 pt; all after cycle 1).
  • In 6 pts evaluable for efficacy, stable disease have been noted in 5 pts for 3 to +7 cycles, including 3 of 3 pts (one refractory) with MCL and 2 of 2 pts (both refractory) with HD.
  • Tumor shrinkage of 43 to 49% have been found in 1 HD and 2 MCL pts after cycle 2.
  • CONCLUSIONS: Oral Bel can be delivered safely with a d 1-14, q3w schedule in pts with lymphoma at a daily dose higher than what has been established for pts with solid tumors.
  • No protocol defined DLTs have yet been encountered in the dose range 750 to 1250 mg QD in pts with lymphoma.
  • Final evaluation will include additional pts and possible dose escalation.
  • The safety profile and early tumor shrinkage noted in MCL and HD warrants continued evaluation of Bel, especially in combination with other active compounds.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962263.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Matasar MJ, McCallen LN, Riedel ER, Ford JS, Oeffinger KC, Straus DJ: Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol; 2009 May 20;27(15_suppl):8547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood.
  • : 8547 Background: Increased late mortality and morbidity have been observed among adult survivors of Hodgkin lymphoma (HL) treated in childhood, but are less well characterized for patients treated in adulthood.
  • The study population consisted of all patients treated on one of 6 consecutive first-line trials of combined modality therapy (CMT), one of which included a chemotherapy-only arm.
  • At time of survey, 227 patients (30.4%) had died: 107 deaths from HL, 100 from causes other than HL, and 20 from unknown cause ( Table 1 ).
  • Cumulative risk of death due to HL is surpassed by causes other than HL by 22 years post-treatment.
  • The most prevalent severe morbidities included second primary malignancy (SPM) (17%), cardiovascular (CV) (18%) and neurologic (18%) disease.
  • CONCLUSIONS: Among adults treated on trials of CMT, by 22y post-treatment the risk of death due to HL is surpassed by risk of death due to other causes.
  • Survivors of HL treated during adulthood experience substantial late morbidity.
  • These findings underscore the importance of efforts directed at prevention of and early intervention for late morbidity in adult survivors of HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960964.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Lossos I, Craig MD, Tallman MS, Boccia RV, Conkling PR, Becerra C, Komarnitsky PB, Hamilton BL, Lewis J, Miller WH: Novel organic arsenic molecule darinaparsin: Development of IV and oral forms. J Clin Oncol; 2009 May 20;27(15_suppl):8501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Darinaparsin i.v. activity in lymphoma is being evaluated in a phase II study.
  • METHODS: Phase II trial is being conducted in patients diagnosed with advanced lymphomas who had ≥ 1 prior therapy.
  • Phase I oral dose escalation studies are being conducted in patients with advanced malignancies and explore safety, MTD, DLTs and preliminary efficacy of continuous and intermittent dosing schedules.
  • Starting continuous dose is 100 mg BID for 3 weeks with 1 week rest, starting intermittent dose is 300 mg twice weekly for 3 weeks followed by 1 week rest.
  • RESULTS: The phase II study has accrued 28 lymphoma patients (21 non-Hodgkin's, 7 Hodgkin's); median age at baseline 61 years, ECOG ≤2, median number of prior therapies 3.
  • Of these, 1 subject (PTCL) has achieved a complete response, 3 - partial responses (2 marginal zone, 1 Hodgkin's), and 4 stable disease (2 PTCL, 1 DLBCL, 1 Hodgkin's).
  • A total of 63 cycles of darinaparsin have been administered to subjects with lymphoma. No Gr.
  • Current darinaparsin dose levels: continuous 200 mg BID, 2× weekly 900 mg.
  • CONCLUSIONS: Darinaparsin is active in heavily pretreated patients with advanced lymphoma and has been very well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Boyle H, You B, Fronton L, Ribba B, Girard P, Tranchand B, Tod M, Coquelin H, Droz J, Flechon A: Major prognostic value of modeled AUC&lt;sub&gt;hCG-AFP&lt;/sub&gt;, a dynamic kinetic marker characterizing tumor marker decline of nonseminomatous germ cell tumors (NSGCT) intermediate-poor-risk patients according to the IGCCCG. J Clin Oncol; 2009 May 20;27(15_suppl):5085

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This may be due to the inaccuracy of methods employed so far, simplifying complex exponential decrease curves by a median half-life (HL).
  • AUC<sub>hCG-AFP</sub> was a significant prognostic factor in the univariate analysis on the 2 year PFS (100% vs 73.8% vs 67.7%, p = 0.035) as well as IGCCCG score (poor/intermediate risk groups), primary site (mediastinal/other) and HL<sub>hCG-AFP</sub>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Brell JM, Hardacre J, Schulak J, Onders R, Stellato T, Sanabria J, Schulchter M, Strickland L, Sprosty R, Pink J: Characterization of human skeletal muscle in weight-losing pancreatic cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Caspase-3, pAkt, and urinary 3-methylhistidine (u3-MH) were assessed by Western blot and high-performance liquid chromatography.
  • Two hundred differentially over- and under-expressed genes were examined in group A for potential association with cachexia.
  • Baseline u3-MH (p=0.86) and FFM (p= 0.28) did not differ; baseline BMI was lower in group A (p=0.04).
  • In 65% patients, progressive disease was noted within median time of 3 months.
  • CONCLUSIONS: Muscle proteolysis in human PC skeletal muscle was not demonstrated, perhaps due to unmeasurable proteolysis or use of non-informative endpoints.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963662.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Tagawa ST, Parmar S, Pena J, Petrillo K, Matulich D, Selzer J, Vallabhajosula S, Goldsmith SJ, Bander NH, Nanus DM: Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16004 Background: Reversible myelosuppression is the dose-limiting toxicity of radioimmunotherapy (RIT).
  • Cases of marrow damage, including myelodysplasia and acute leukemia have been reported with the RIT most used to date (that targeting CD20 in Non- Hodgkin's lymphoma), though no statistically significant association exists.
  • 80 received <sup>177</sup>Lu-J591 at cumulative doses ranging from 10-120 mCi/m<sup>2</sup> and 29 received <sup>90</sup>Y-J591 at cumulative doses of 5-40 mCi/m<sup>2</sup>.
  • 43% received at least 1 line of pre-RIT chemo, 53% received at least 1 line of post-RIT chemo, and 20% have never received chemo to date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Gundrum JD, Go R, Kwong R: Cancer in the oldest old population in the United States: Current statistics and projections. J Clin Oncol; 2009 May 20;27(15_suppl):9553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 10 leading cancers by incidence (both sexes and decreasing order) are colorectal (388.9), lung (287.7), breast (250), prostate (211.5), urinary bladder (162.5), non-Hodgkin lymphoma (110.9), leukemia (85.1), melanoma (65), renal (46.4), and uterine (40.2).
  • The incidences of melanoma, non-Hodgkin lymphoma, renal, and lung cancers are increasing, while those of leukemia, prostate, breast, and colorectal cancers are decreasing.
  • Cancer specific survival (CSS) has been increasing continuously since 1973 for melanoma, non-Hodgkin lymphoma, breast, colorectal, prostate, and urinary bladder cancers but decreasing in recent years for colorectal, breast, prostate, and uterine cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963637.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Hentrich M, Gerl A, Lutz L, Karthaus M, Schiel X: Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):e19546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL).
  • Pts received a median of 6 cycles (range 1 - 18) of R.
  • A total of 517 cycles of R were evaluable for OI or UT.
  • UT consisted of interstitial pneumonitis (IP) in 2 pts after 8 and 6 cycles of R-CHOP for diffuse large cell lymphoma (DLCL), a case of congestive heart failure (NYHA III°) after 6x R-CHOP + 2x R-M for follicular lymphoma (FL) and a case of grade 4 pancytopenia lasting for 22 days following 2x R-FC for chronic lymphocytic leukemia.
  • Congestive heart failure improved under appropriate therapy and the pt received 2 more cycles of R-M.
  • OI consisted of pneumocystis jirovecii pneumonia after 5x R-CHOP-14 for DLCL, Epstein-Barr-virus (EBV)-associated hepatitis after 5x R-CHOP-21 for relapsed FL and generalized herpes zoster following 6x R-bendamustine (RB) + 1x R-M for recurrent BALT-lymphoma.
  • Moreover, 2 pts were transferred to us for therapy of enterovirus-induced encephalitis after 6x R-CHOP-21 + 2x R-M for FL (n=1) and cerebral toxoplasmosis in a pt heavily pretreated with R-containing therapy for relapsed mantle cell lymphoma (n=1).
  • In selected cases reexposure of R may be feasible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Willett EV: Non-Hodgkin lymphoma and obesity. Int J Cancer; 2008 Jul 15;123(2):491-492

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma and obesity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28921491.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


47. Bartlett N, Forero-Torres A, Rosenblatt J, Fanale M, Horning SJ, Thompson S, Sievers EL, Kennedy DA: Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol; 2009 May 20;27(15_suppl):8500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL).
  • : 8500 Background: A defining feature of HL and sALCL is CD30 expression on malignant cells.
  • In a previous phase 1 study with q3 wk dosing, 54% of pts achieved an objective response (CR/PR) at SGN-35 doses ≥1.2 mg/kg [ASH 2008 abstract 1006].
  • METHODS: To assess if more frequent dosing might maximize anti-tumor activity with acceptable tolerability, a multicenter, phase 1, weekly dosing, dose-escalation study (3+3 design) was conducted in pts with refractory or recurrent HL or sALCL.
  • SGN-35 was administered weekly at doses of 0.4-1 mg/kg (2-hr IV infusions).
  • Pts with stable disease or better (Cheson 2007) after two 28-day cycles (6 doses) were eligible to continue SGN-35 treatment.
  • Exposure to SGN-35 (AUC) increased relative to dose level.
  • Multiple CRs were observed at higher doses ( table ); observed time to response in the 1 mg/kg dose group was approximately 8 wks.
  • CONCLUSIONS: SGN-35 was generally well tolerated and induced CRs in 7 of 8 evaluable pts at the two highest doses in heavily pretreated patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Kurt BA, Nolan VG, Ness KK, Neglia JP, Tersak JM, Hudson MM, Armstrong GT, Leisenring WM, Robison LL, Arora M: Hospitalization rates among survivors of childhood and adolescent cancer: A report from the Childhood Cancer Survivor Study (CCSS). J Clin Oncol; 2009 May 20;27(15_suppl):9556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Associations between demographic, cancer/treatment-related risk factors and non-obstetrical hospitalization among survivors were evaluated in multiple variable logistic regression models.
  • RESULTS: At follow-up, survivors were a mean of 20.9 yrs. from diagnosis (SD: 4.6, range: 13.3-32.2) and mean age of 28.6 yrs. (SD: 7.7, range: 13-51).
  • Increased risk of hospitalization was noted irrespective of gender, age at follow-up, or cancer diagnosis, with highest SIRs noted for male (SIR=12.7, 95% CI 9.5-15.8) and female (SIR=72.1, 95% CI 58.8-85.5) survivors aged 45-54.
  • Females (OR=1.2, 95% CI 1.04-1.3) and survivors with a chronic health condition (OR=1.6, 95% CI 1.5-1.8) were more likely to have been hospitalized for non-obstetrical causes after adjusting for age at diagnosis, age at follow-up, cancer diagnosis, household income, insurance, and history of relapse/second malignancy.
  • Among survivors, those with Hodgkin's lymphoma had the highest hospitalization rates for neoplastic, infectious, endocrine, pulmonary and cardiovascular causes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963638.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Comandone A, Boglione A, Pochettino P, Berno E, Inguì M, Papotti M, Borasio P, Maggi G, Brach Del Prever E, Gino G: Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):e21509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas.
  • : e21509 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • Pts characteristics: median age 41 (19-80 y), male/female 19/12; symptoms at diagnosis: dyspnoea (42%), chest and shoulder pain (39%), cough (35%), hemophtoae (13%), discomfort (10%).
  • 4 pts had a previous history of mediastinal radiation for Hodgkin's and non-Hodgkin's linfomas.
  • 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart).
  • 26 lung sarcomas presented as a singular mass in 23 cases and as a metastatic disease in 3.
  • RESULTS: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • Local relapse or metastatic progression were recorded in 16/23 pts and 12 received one or more lines of palliative CT.
  • Of these only 8 are alive (2 with disease).
  • Volume of disease, complete resection and grading are the dominant prognostic factors.
  • CONCLUSIONS: Primary sarcomas of the lungs and mediastinum have a very severe prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Chen B, Mahmud F, Mangel J, Vujovic O, Rieder M, Zelcer S: Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation. J Clin Oncol; 2009 May 20;27(15_suppl):e19526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation.
  • : e19526 Background: Mediastinal radiation (RT) is a cause of premature coronary artery disease (CAD) in Hodgkin lymphoma survivors (HLS).
  • Peripheral arterial tonometry (PAT) is a non-invasive technique that measures endothelial function (EF), as a surrogate marker of sub-clinical atherosclerosis.
  • The objective of our study was to evaluate EF in HLS and age-matched controls using PAT and to determine the association of mediastinal RT.
  • METHODS: Cross sectional evaluation of 26 HLS age 12-30 years and within a minimum of two years from the completion of therapy and matched controls.
  • RESULTS: HLS and controls were similar for baseline variables (mean age 23.2 ± 5 yrs; 23.4 ± 4.6 yrs, p=0.35).
  • HLS were on average 9.9 ± 3.9 yrs post treatment.
  • No differences in EF or cardiovascular risk factors were observed between HLS survivors and controls.
  • However impaired EF, as evidenced by lower PAT-HR (1.66 ± 0.18 vs. 2.08 ± 0.38, p<0.01) was seen in HLS (n=13) who received mantle/mediastinal RT (mean RT dose 2657 ± 971 cGy) compared to controls.
  • Mean cumulative anthracycline dose did not differ between HLS who did or did not receive RT (224.1 ± 65.4 vs. 253 ± 70.3 mg/m<sup>2</sup> p=0.18).
  • These differences were not explained by alterations in lipoproteins or hsCRP, however activity scores were significantly lower in HLS compared with young adult controls (2.01 ± 1.1 vs. 3.6 ± 1.2 hrs daily, p=0.02).
  • CONCLUSIONS: Impaired EF was observed in a small group of HLS who received mediastinal RT as compared to those who did not.
  • Cancer survivors at risk may benefit from early assessment of EF as a sub-clinical marker of CAD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Srinivas S, Cholankeril M, Chang VT, Morales-Muyuela E, Duque L, Toomey K, Kasimis B: Non-Hodgkin's lymphoma (NHL) patients at a VA medical center: Comorbidity and treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e19559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma (NHL) patients at a VA medical center: Comorbidity and treatment.
  • : e19559 Background: We hypothesized that measures of comorbidity may help explain the number of treatments administered to patients with non-Hodgkin's lymphoma.
  • METHODS: We performed a retrospective, IRB approved protocol, using chart review of all patients diagnosed with non-Hodgkin's lymphoma at the VANJHCS from January 1, 1997 through December 31, 2008.
  • Records were reviewed for demographic, clinical, pathological data, the number of chemotherapy regimens, radiation therapy, and total number of treatments and survival.
  • We tabulated the Charlson Comorbidity Index (CMI), the Kaplan-Feinstein Comorbidity Index (KFI), the Cumulative Illness Rating Scale (CIRS), International Prognostic Index (IPI), and performance status (PS) were tabulated for 100 patients seen at a VA Medical Center.
  • The M total number of systemic therapy regimens received was 1(0-4.5), M radiotherapy was 0(0-1) and the overall M total treatment regimens used was 1 (0-4.5).
  • IPI was a significant predictor in the use of radiation therapy (p<0.054) but did not correlate with the use systemic therapy.
  • The CMI was a predictor of the use of systemic chemotherapy (p<0.007), and the total number of treatments received (p<0.011), but not the KFI or the CIRS 17.
  • CONCLUSIONS: This data provides evidence that one measure of comorbidity, the CMI, may partially explain the number of systemic therapy treatments, and total treatments received by NHL patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961077.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Gil Deza E, Dragosky M, Annetta I, Marquez M, Corzo A, Gercovich N, Morgenfeld E, Tognelli F, Rivarola E, Gercovich FG: Primary breast lymphomas: An Argentinian cooperative study. J Clin Oncol; 2009 May 20;27(15_suppl):e19555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast lymphomas: An Argentinian cooperative study.
  • : e19555 Background: Primary Breast Lymphomas are rare tumors (less than 1% of all primary breast tumors).
  • Because of that, the records of two institutions dedicated exclusively to the treatment of cancer (Hospital Municipal de Oncologia "Maria Curie" and Instituto Oncologico Henry Moore) have been working together in a single series.
  • OBJECTIVE: To make a retrospective study of the clinical onset, treatment and evolution of the patients with Primary Breast Lymphoma (PBL).
  • A database containing characteristics of the population, clinical onset, treatments, evolution and survival Results: Gender F/M=2/15 pt.
  • Pathology: Hodgkin's Lymphoma = 1 pt, NHL follicular = 8 pt, Large-Cell Diffuse NHL = 6 pt, lymphoplasmocytic NHL = 1 pt, Marginal Zone NHL = 1 pt.
  • 2) Sixteen out of 17 were non-Hodgkin lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961091.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Ghosh J, Kumar L, Saxena R, Raina V, Sharma A, Gupta R, Vivekanandhan S, Sreenivas V, Verma R: A study of the prevalence and type of anemia in lymphoid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e19556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of the prevalence and type of anemia in lymphoid malignancies.
  • METHODS: Newly diagnosed patients of lymphoid malignancy- non Hodgkins lymphoma (NHL), Hodgkins lymphoma (HL), and chronic lymphocytic leukemia (CLL) aged more than 15 years without renal failure and who had not received blood transfusion, iron, folic acid or vitamin B complex in the last 2 weeks were analyzed.
  • Of the anemic patients (hemoglobin <11gm/dl), 46 were studied for the type of anemia.
  • Anemia was categorized as due to either autoimmune hemolytic anemia (AIHA)-DCT positive with evidence of hemolysis on PBS, B12 and folate deficiency (<200 pgm/ml and < 4ngm/ml respectively), iron deficiency anemia (IDA)- psat <20% and SF315μgm/dl, anemia of chronic disease (ACD)-psat200μgm/L, a combination of IDA and ACD -psat <20%, SF -30-200 with TIBC ≤315 μgm/dl.
  • CONCLUSIONS: Although anemia of chronic disease is the most common cause of anemia in patients with lymphoid malignancy, it is multifactorial in a large number of patients and hence it is important to rule out other causes of anemia like nutritional and AIHA in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961090.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Barron R, Michels SL, Reynolds MW, Tomic K, Yu J, Lyman G: Risk of mortality in patients with cancer experiencing febrile neutropenia. J Clin Oncol; 2009 May 20;27(15_suppl):9561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk of mortality from FN is not well characterized in clinical practice.
  • METHODS: Patients with cancer receiving chemotherapy in clinical practice were identified from the HealthCore Integrated Research Database, a geographically diverse spectrum of fully adjudicated longitudinal claims data from 13 health plans with over 20 million US lives.
  • Patients experiencing FN were compared to propensity score-matched patients not experiencing FN within tumor types of Non-Hodgkin lymphoma (NHL), breast, lung, colorectal and ovarian cancer.
  • Prevention of FN is of high importance and should be carefully considered in clinical practice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963629.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Lansigan F, Cooper D, Seropian S, Foss F: Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):8558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience.
  • : 8558 Aggressive T-cell lymphomas (ATCL) represent 10-15% of non-Hodgkin lymphoma and have a worse prognosis than aggressive B-cell lymphomas.
  • The Auto group consisted of 6 PTCLu, 12 ALCL (5 Alk+, 5 Alk-, 2 Alk unk), 4 AITL, 1 CTCL with transformation, and 1 T-lymphoblastic lymphoma.
  • Median time from diagnosis to Allo or Auto was 18 and 8mo, respectively.
  • The non-relapse mortality was 33%(Allo) and 8%(Auto).
  • Within the Auto group, 14(58%) were transplanted in first complete remission(CR1), and 10(42%) in CR2, beyond CR2, or PR.
  • Patients in CR1 had significantly better PFS (57 vs 17mo, p=0.007) and OS (76 vs 29mo, p=0.004) than those in CR2, beyond CR2, or PR.
  • For patients with resistant or relapsed disease, Allo should be strongly considered rather than Auto.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960993.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Henderson TO, Hlubocky F, Diller L, Daugherty C: Preferences and knowledge gaps among pediatric oncologists regarding the care of childhood cancer survivors: A survey of nearly 1,200 physicians. J Clin Oncol; 2009 May 20;27(15_suppl):6561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A second mailing for non-responders is planned.
  • Choosing from closed-ended responses: 37% say they prefer to follow CCS as long as possible, 21% prefer for the patients to be followed by a physician other than themselves, and 29% are willing to follow them in the absence of a more suitable physician.
  • In a clinical vignette of 29 year old women exposed to mantle radiation and anthracyclines (150 mg/m2) for Hodgkin's lymphoma at 16 years of age: 30% of respondents did not appropriately recommend yearly breast cancer surveillance (based on Children's Oncology Group LTFU guidelines); 41% of respondents did not appropriately recommend cardiac surveillance; and 15% of respondents did not appropriately recommend yearly thyroid screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Indelicato DJ, Keole SR, Shahlaee AH, Morris CG, Gibbs CP, Scarborough MT, Islam S, Marcus RB: Ewing tumors of the chest wall: Local control and long-term outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):e21501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21501 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • Pts characteristics: median age 41 (19-80 y), male/female 19/12; symptoms at diagnosis: dyspnoea (42%), chest and shoulder pain (39%), cough (35%), hemophtoae (13%), discomfort (10%).
  • 4 pts had a previous history of mediastinal radiation for Hodgkin's and non-Hodgkin's linfomas.
  • 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart).
  • 26 lung sarcomas presented as a singular mass in 23 cases and as a metastatic disease in 3.
  • RESULTS: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • Local relapse or metastatic progression were recorded in 16/23 pts and 12 received one or more lines of palliative CT.
  • Of these only 8 are alive (2 with disease).
  • Volume of disease, complete resection and grading are the dominant prognostic factors.
  • CONCLUSIONS: Primary sarcomas of the lungs and mediastinum have a very severe prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF: Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
  • : e19554 Background: Multiple reports corroborate a role for irinotecan in the treatment of lymphoma.
  • This study describes the Memorial Sloan Kettering experience with single-agent irinotecan in the management of heavily pretreated and highly refractory cases of lymphoma.
  • METHODS: Adult patients with histologically diagnosed relapsed or refractory lymphoma treated with irinotecan between 1/2001 and 8/2008 were identified.
  • Treatment responses were evaluated based on the Revised Response Criteria for Malignant Lymphoma.
  • 4 patients had Hodgkin Lymphoma (HL) and 26 had Non-Hodgkin lymphoma (NHL): 17 DLBCL, 6 transformed follicular lymphoma, 1 mantle cell lymphoma, 1 T-cell lymphoma and 1 Burkitt's. 25 patients were evaluable for response.
  • 5 achieved an objective response (overall response rate 20%); 2 achieved complete remission (CR) and 3 partial remissions (PR).
  • 8 patients (32%) had stable disease and 12 (48%) progressed on treatment.
  • CONCLUSIONS: Irinotecan has utility even in multiply treated and highly refractory cases of lymphoma.
  • It can mitigate symptoms resulting from bulky disease and shows potential as a palliative treatment option.
  • Strategies that limit adverse reactions may enhance the agent's effectiveness in refractory lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Naina HV, Pruthi RK, Litzow MR, Ansell SM, Dispenzieri A, Hogan WJ, Gertz MA, Elliott MA, Gastineau DA, Kumar SK: Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. J Clin Oncol; 2009 May 20;27(15_suppl):7039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We included only patients with a diagnosis of AL amyloidosis (AL), multiple myeloma (MM) Hodgkin's lymphoma (HL) and non Hodgkin's lymphoma (NHL).
  • Patients' demographic details and diagnosis of VTE were collected from electronic medical records.
  • Of the 631 patients, 278 (44%) MM, 209 (33%) NHL, 114 (18%) AL, and 20 (3%) had HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Zhang M, Huck J, Hyer M, Ecsedy J, Manfredi M: Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. J Clin Oncol; 2009 May 20;27(15_suppl):8553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models.
  • In this study we explored the anti-tumor effect of MLN8237 in vivo in pre-clinical models of human Diffuse Large B-cell Lymphoma (DLBCL) both as a single agent and in combination with the anti-CD20 monoclonal antibody Rituximab.
  • RESULTS: MLN8237 induced anti-tumor activity that was dose-dependent in all three models.
  • In the primary lymphoma model, MLN8237(10-20mg/kg) caused a significant anti-tumor effect during treatment period (TGI = 83-95%).
  • MLN8237 is currently being tested as a single agent in a phase I clinical trail in patients with DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960986.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hoskin P, Czuczman MS: Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):8543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL).
  • Studies were conducted in rituximab sensitive (RSCL) and resistant cell lines (RRCL), as well as in malignant B-cells derived from patients with NHL (n = 20).
  • Cells were exposed in vitro to escalating doses of O with/without B.
  • To further study the mechanisms of O and/or B action, RSCL or RRCL were exposed to O or B with or without caspase inhibitors; viability was evaluated as above and apoptosis by flow cytometry and PARP cleavage.
  • O or B monotherapy induced time- and dose-dependent cell death of all cells tested.
  • In vitro exposure of RRCL, RSCL and lymphoma specimens to O and B resulted in significant synergistic activity.
  • The ability of O or B to induce PARP cleavage varied between patient samples and was not observed in RRCL.
  • Inhibition of caspase activity did not affect the ability of O or B to kill NHL cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Andorsky DJ, Yamada R, Steward K, De Vos S, Said J, Timmerman J: Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells. J Clin Oncol; 2009 May 20;27(15_suppl):8526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells.
  • : 8526 Background: PD-L1 is expressed on antigen presenting cells and inhibits activation of T cells through its receptor, PD-1.
  • METHODS: PD-L1 expression was analyzed in 16 NHL cell lines by flow cytometry (FC) and in 111 lymphoma specimens by immunohistochemistry (IHC) (n=92) or FC (n=19).
  • In functional studies, irradiated anaplastic large cell lymphoma (ALCL) cells were co-cultured with allogeneic T cells in the presence of anti-PD-L1 blocking antibody, and IFNγ secretion and thymidine incorporation was used to assess T cell function and proliferation.
  • To further test tumor-T cell interactions, malignant ascites from a patient with ALK+ ALCL and peripheral blood mononuclear cells from a patient with leukemic mantle cell lymphoma, both containing PD-L1-expressing tumor cells and tumor-associated T cells, were stimulated with phytohemagglutinin (a polyclonal T cell activator) and incubated with anti-PD-L1 antibody.
  • Levels of 16 inflammatory cytokines were measured as an assessment of T cell activity.
  • RESULTS: All 9 B cell lymphoma lines were negative for PD-L1, while all 5 ALCL cell lines were strongly positive.
  • One T-cell ALL line was positive, and one peripheral T cell lymphoma was negative.
  • Strong PD-L1 staining was detected by IHC in all 14 ALCL specimens and in 83% of diffuse large B cell lymphomas (DLBCL) analyzed (n=35).
  • In the autologous setting using cultures of ALCL and mantle cell lymphoma specimens containing host T cells, secretion of inflammatory cytokines by tumor-associated T cells, including GMCSF, IFNγ, IL-1, IL-6, IL-8, TNFα, and MIP1α, were increased by incubation with anti-PD-L1 antibody.
  • PD-L1 may play a role in thwarting an effective anti-tumor immune response and represents an attractive target for lymphoma immunotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960901.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Pettengell R, Narayanan G, Mendoza FH, Digumarti R, Gomez H, Cernohous P, Gorbatchevsky I: Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma.
  • Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone, has potentially reduced cardiotoxicity and has demonstrated promising clinical activity in phase II studies in heavily pretreated NHL patients.
  • METHODS: PIX301 was a controlled, multicenter, open-label phase III study of ≥ third-line treatment of relapsed aggressive (de novo or transformed) NHL.
  • All patients were required to have received ≥ 1 prior anthracycline-containing regimen, with the cumulative doxorubicin-equivalent dose limited to ≤ 450 mg/m<sup>2</sup>.
  • Randomization was to pixantrone 85 mg/m<sup>2</sup> on days 1, 8 and 15 of 28-day cycles, for up to 6 cycles, or to investigator's choice of a single-agent comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, or mitoxantrone; in the US only, gemcitabine and rituximab were permitted).
  • CONCLUSIONS: In this study, single-agent therapy with pixantrone achieved significantly superior CR/CRu and ORR rates in ≥ third-line treatment of relapsed/refractory aggressive NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960900.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Schilling MB, Parks C, Deeter RG: Costs and outcomes associated with febrile neutropenia-related hospitalizations across patients with varying cancer types: A retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20560 Background: Neutropenia, the major dose-limiting toxicity of chemotherapy, is a frequent, often serious, and sometimes fatal complication of myelosuppressive chemotherapy.
  • Its economic and clinical impact is often under-appreciated, and thus this study evaluates the contribution of febrile neutropenia (FN) by tumor type as related to healthcare cost and mortality.
  • METHODS: FN patients in this study were identified as having cancer (ICD-9-CM: 140.xx - 208.xx), neutropenia (288.0x) and either opportunistic infections (110 total codes) or fever of unknown origin (780.6) who were hospitalized between 1/05 and 6/08 in a retrospective cohort study from the Aspen US healthcare database (∼11 million pts, >342 inpatient facilities, and >300 million charge-detail records).
  • Unadjusted mean healthcare cost of hospitalization, length of hospital stay (LOS), and mortality rates were calculated, stratifying by cancer type (breast, metastatic breast, and lung cancers, non-Hodgkin lymphoma (NHL), or other hematologic tumors).
  • RESULTS: Among 598 hospitalized patients (mean age 63 years; 53% female) with cancer experiencing FN, the mean cost of hospitalization, LOS and mortality varied significantly by tumor type ( Table ).
  • The tumor type is important in assessing the economic and clinical impact of FN hospitalizations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961149.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Masuda N, Ando M, Aogi K, Ino H, Iwata H, Tokuda Y, Nakamura S, Yamamoto N, Fujiwara Y: Randomized phase II study of neoadjuvant chemotherapy and trastuzumab for operable breast cancer with overexpression of HER2. J Clin Oncol; 2009 May 20;27(15_suppl):565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 565 Background: Achievement of pathological complete response (pCR) by primary systemic therapy (PST) correlates with improved survival in operable breast cancer patients.
  • Based on data of the higher pCR rate with concomitant chemotherapy and trastuzumab (H) reported by some clinical trials, we performed a multi-center, prospective randomized phase II study to evaluate the efficacy of adding H to standard chemotherapy and to determine more effective agent which will show higher pCR by the comparison between weekly paclitaxel (P) and tri-weekly docetaxel (D) in neo-adjuvant setting for HER-2+ pts.
  • PST regimen was scheduled as the sequential chemotherapy with 4 cycles of CEF (cyclophosphamide, epirubicin 100 mg/m<sup>2</sup>, 5FU) followed by 4 cycles of q3w H with qw P 80 mg/m<sup>2</sup> (HP) or q3w D 75 mg/m<sup>2</sup> (HD).
  • RESULTS: From March 2007 to June 2008, 102 pts were enrolled and randomized as well balance in the same number, median age (51yo), and the same distribution of clinical stage.
  • Pre-matured data was available for 60 pts whom central review had been completed: there was no significantly difference in pCR rate between two groups, 53% (95%CI: 35.4-71.1%) on HP and 47% (28.8-64.5%) on HD.
  • CONCLUSIONS: In HER-2+ pts, PST with CEF followed by HP or HD might be equally active and achieving high pCR without significant toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960723.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Vera L, Reategui R, Beltran B, Morales D, Capellino A, Desposorio C, Castillo J: The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathological spectrum of HIV-associated lymphoma: Eleven-year-experience in a general hospital in Peru.
  • : e19561 Background: The clinicopathological spectrum of HIV-associated lymphomas in developing countries has not been clearly defined.
  • METHODS: This is a retrospective review of the clinical records of patients with diagnosis of HIV in our institution from March 1997 to March 2008.
  • We reviewed 2502 clinical records.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • 32 patients (67%) had clinical stage III-IV, B symptoms 35 (73%), the International Prognostic Index was low-risk 20 patients (42%), low-intermediate risk 15 patients (31%), high-intermediate risk 10 patients (21%) and high-risk 3 patients (6%).
  • Forty-four cases (92%) were diagnosed with non-Hodgkin lymphoma (NHL) and 4 cases (8%) with Hodgkin lymphoma (HL).
  • From the 44 NHL cases, 40 cases (91%) were of B-cell origin; 23 cases (57.5%) had diffuse large B-cell, 9 cases (22.5%) had Burkitt, 3 cases (7.5%) had plasmablastic, 2 cases (5%) had primary CNS, 2 cases (5%) had MALT and 1 case (2.5%) had primary effusion lymphoma.
  • The remaining 4 cases (9%) were of T-cell origin; 3 cases (75%) had peripheral T-cell lymphoma NOS and 1 case (25%) was ALK-negative anaplastic large cell lymphoma.
  • Only 16 patients (33%) were receiving HAART previously the diagnosis of NHL and 33 patients (68%) received any oncology treatment.
  • Also a high proportion of T-cells lymphomas are found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961062.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Kohrt HE, Advani R, Hoppe R, Rosenberg S, Horning S, Lee PP: Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease. J Clin Oncol; 2009 May 20;27(15_suppl):8573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease.
  • : 8573 Background: Multiple translational efforts in HD are actively investigating augmentation of the anti-tumor immune response by stimulating cytotoxic T lymphocytes (CTL) against tumor-associated EBV antigens.
  • It has previously been believed that this therapeutic strategy and presence of EBV-specific CTLs are limited to EBV-positive HD.
  • Here, we challenge this belief by characterizing EBV-specific CTL responses in EBV-negative HD.
  • METHODS: Among 52 consecutive patients with EBV-negative HD, CTL responses to latent antigens (LMP2, LMP2a) and lytic antigens (BMLF, BRLF) were serially assessed at diagnosis, during chemotherapy, and throughout followup for 2 years by IFN-γ Elispot and flow cytometric tetramer analysis.
  • RESULTS: We detected weak EBV-specific responses to both lytic and latent antigens by IFN-γ Elispot among patients with EBV-negative HD.
  • Chemoradiotherapy was associated temporally with an initial decrease in LMP2A- and BMLF1-specific responses during the first 5-15 weeks of treatment, which subsequently became more robust 20-50 weeks after diagnosis, 2 to 4-fold greater compared to response at diagnosis.
  • CONCLUSIONS: We confirm evidence of EBV-specific CTLs in patients with EBV-negative HD and provide the first report of dynamic variance in this population during treatment, challenging prior belief that patients with HD remain immunodeficient following therapy and arguing that the clinical significance of EBV-specific immune responses in EBV-negative HD should be further investigated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Flowers C, Sinha R, Kaufman J, Shenoy P, Lewis C, Bumpers K, Rogatko A: Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results. J Clin Oncol; 2009 May 20;27(15_suppl):8577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results.
  • : 8577 Background: Adding rituximab (R) to chemotherapy improves survival for patients (pts) with follicular lymphoma (FL) and other indolent non-Hodgkin lymphomas (NHL), but not all pts respond.
  • Bortezomib (B) + RCHOP has a high complete response (CR) rate, but higher doses of B with standard vincristine produced severe neuropathy.
  • The maximum tolerated dose (MTD) was defined as the regimen at which <30% grade ≥3 non-hematological or grade ≥4 hematological toxicity (>14 days) occurs.
  • Dose escalation used the Escalation with Overdose Control Bayesian method with upper bound (θ=0.3).
  • This facilitated MTD finding with fewer pts given prior data on B+RCHOP.
  • 6 pts (55%) had stage IV disease; 8 (64%) had FLIPI ≥2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962274.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Paoluzzi L, Scotto L, Seshan VE, O'Connor OA: Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL). J Clin Oncol; 2009 May 20;27(15_suppl):8584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL).
  • HDACIs are known to induce cell death in malignant cells through multiple mechanisms, including up-regulation of death receptors, disruption of Hsp90 function and generation of reactive oxygen species.
  • Mantle cell lymphoma is an aggressive subtype of non-Hodgkin lymphoma characterized by the reciprocal translocation t(11;14)(q13;q32) leading to the overexpression of cyclin D1.
  • METHODS: We investigated the cytotoxicity of romidepsin and belinostat alone and in combination with the proteasome inhibitor bortezomib in cell lines of mantle cell lymphoma (HBL2, Granta519, Jeko1).
  • RESULTS: The IC<sub>50</sub> values for R and B alone at 24 hours were: HBL-2: R=4.7nM, B=490nM; Jeko-1: R=3nM, B=750nM; Granta519: R=45nM, B=30,700nM.
  • The combination of belinostat (100-1000nM) or romidepsin (1-40nM) with bortezomib (3-4nM) showed synergism in all cell lines at different concentrations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962269.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Papadopoulos A, Vrettos I, Kamposioras K, Charitos D, Giannopoulos G, Pectasides D, Niakas D, Economopoulos T: Comparing health-related quality of life (HRQL) of cancer patients undergoing chemotherapy with family members in a tertiary hospital. J Clin Oncol; 2009 May 20;27(15_suppl):e20535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SF-36 health survey was used to evaluate and compare HRQL which contains eight scales measuring physical functioning (PF), role physical (RP), bodily pain (BP), general health perception (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH), with higher scores (0-100 range) reflecting better-perceived health.
  • CONCLUSIONS: Although the physical health was significantly higher in the family members as it was expected for a healthy population, the mental health and especially MCS was significantly lower from the cancer patients undergoing chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960974.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Knop S, Liebisch P, Wandt H, Kropff M, Jung W, Kroeger N, Sezer O, Straka C, Fingerle-Rowson G, Einsele H: Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM Xia trial. J Clin Oncol; 2009 May 20;27(15_suppl):8516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8516 Background: Cytoreductive induction followed by HD-MEL and ASCT is considered standard of care for younger patients (pts) with multiple myeloma (MM).
  • The first 30 pts were included in the dose finding study to determine the optimum dose of IV C in conjunction with Vel and D.
  • Primary study objective is response rate (≥ PR) to VelCD according to the EBMT criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960882.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Jajeh A: Reccurent and prolonged panctopenia with rituximab therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This drug has been implemented in the treatment of B cell lymphoproliferative disorders as well as non-neoplastic disease such as autoimmune thrombocytopenia, immune hemolytic anemia and other disorders related to overexpression of antibodies against the host.
  • One patient, a female( age 33) had rheumatoid arthritis and the rest had non hodgekin's lymphoma.
  • None of the patients with non hodgkin's lymphoma had bone marrow involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961092.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Braun E, Katz D, Venugopal P, Larson M, Shammo J, Fung H, Gregory S: Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy.
  • : e19529 Background: Radioimmunotherapy is a therapeutic option for relapsed or refractory indolent, follicular and transformed non Hodgkin's lymphoma and mantle cell lymphoma.
  • Groups characteristics such as sex, type of RIT, presence of disease in bone marrow, FLIPI/IPI and use of G-CSF were noted.
  • CONCLUSIONS: RIT should be considered a safe therapeutic modality in patients with refractory or relapsed indolent, follicular, NHL, transformed and Mantle Cell lymphoma regardless of age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960911.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Ngeow JY, Quek R, Tao M, Tan HC, Lim L, Tan I, Kaneswaran R, Lim ST: Analysis of long-term treatment outcomes and toxicty of HL. J Clin Oncol; 2009 May 20;27(15_suppl):e19536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term treatment outcomes and toxicty of HL.
  • : e19536 Background: Prognosis of patients with Hodgkin lymphoma (HL) has substantially improved but therapy of HL can however contribute to delayed toxicity.
  • Long term treatment outcomes of HL in our local population were evaluated.
  • METHODS: Clinical and treatment data was prospectively collected from all patients with a histological diagnosis of HL.
  • Patients who were young (< 30 years) were more likely to present with nodular sclerosis HL (p=0.0001).
  • 5 year OS for early stage HL was 92% and 88% for advanced stage HL.
  • Of note, comparing patients with early stage (Stage I/ II) HL (n=114) who had ABVD 4 cycles followed by involved field radiotherapy (IFRT) with those who received 6-8 cycles of ABVD, there was no difference in OS, FFTF (p= 0.99, 0.48 respectively).
  • Bulky early stage HL who received 6 cycles of ABVD and IFRT had better FFTF rates than those who had just 4 cycles of ABVD followed by IFRT (p=0.06).
  • In contrast, patients patients with advanced HL (Stage III/ IV) (n=70) who completed 6-8 cycles of ABVD did not benefit from additional IFRT even in the presence of bulky disease (n=15).
  • 1) Epidemiology of HL in Singapore is increasingly similar to that of developed countries with a peak in young adults.
  • 2)Young age was predictive of a nodular sclerosis subtype 3) Abbreviated chemotherapy using 4 cycles of ABVD followed by IFRT performed similarly to 6 cycles of ABVD in early stage HL, but in patients with bulky disease this may not be sufficient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Baum PR, Cerveny C, Gordon B, Nilsson C, Wiens J, Rafiq S, Lapalombella R, Muthusamy N, Byrd JC, Wahl A: Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma.
  • : 8571 Background: TRU-016, a single chain anti-CD37 Fc fusion molecule has been shown to display pro-apoptotic and Fc-dependent cellular cytotoxicity activities against primary CLL cells and NHL cell lines.
  • We have tested drug combinations using the mantle cell lymphoma line Rec-1 and diffuse large B-cell lymphoma line SU-DHL-6 in vitro and extended these results to in vivo settings using the follicular lymphoma cell line DOHH2 treated with the combination of TRU-016 and bendamustine.
  • METHODS: To determine TRU-016 interactions with the established therapeutics rituximab, doxorubicin, rapamycin, and bendamustine, drugs were tested alone or in combination with TRU-016 and the anti-proliferative effects on cell lines measured after 96 hours.
  • This demonstrates that the in vitro synergy results were extendable to a more complex in vivo disease model.
  • Furthermore, the combination of TRU-016 and bendamustine displayed greater in vivo anti-tumor activity than either agent alone against a follicular lymphoma tumor model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Noga SJ, Mo M, Dreiling L, Ozer H: Are comorbidities present in non-Hodgkin's lymphoma (NHL) patients (pts) enrolled in recent clinical trials different from those observed in previous clinical trials? J Clin Oncol; 2009 May 20;27(15_suppl):e19540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are comorbidities present in non-Hodgkin's lymphoma (NHL) patients (pts) enrolled in recent clinical trials different from those observed in previous clinical trials?
  • : e19540 Introduction: Co-morbidities are often more prevalent in community practice than in clinical studies due to an increased mortality risk (Kuderer 2006; Noga 2007).
  • Such co-morbidities may have been formally or informally excluded in earlier clinical trials.
  • CONCLUSIONS: More recent clinical trials tend to enroll older pts compared with earlier trials and tend to include pts with the major co-morbidities often seen in the general NHL population.
  • Clinical practice may also be changing to allow more elderly pts with co-morbidities to receive aggressive chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960999.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Sullivan RJ, Hoshida Y, Brunet J, Tahan S, Aldridge J, Kwabi C, Gardiner E, McDermott D, Golub T, Atkins MB: A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol; 2009 May 20;27(15_suppl):9003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response.
  • : 9003 Background: HD IL-2 remains one of two FDA-approved therapies for the treatment of patients (pts) with advanced melanoma.
  • The toxicity of HD IL-2 limits its application to pts treated in specialized centers.
  • We present the clinical outcome of pts treated over a recent 2 year period with HD IL-2 at a single institution and an associated retrospective pilot study evaluating the predictive value of a novel tumor gene expression signature.
  • METHODS: Clinical and radiological data were collected and analyzed on 49 consecutive pts treated with HD IL-2 at Beth Israel Deaconess Medical Center from 10/05 - 10/07.
  • RESULTS: Clinical response occurred in 16 of the 49 pts (32.6%), with 5 pts (10.2%) having a CR.
  • Two other pts had stable disease > 12 mos; 3 pts who progressed after response had resection to NED.
  • 10 pts remain disease/progression free at a minimum of 16 mos following treatment.
  • CONCLUSIONS: The overall and CR rates in a contemporary series of pts with metastatic melanoma treated with HD IL-2 are twice that reported in initial studies suggesting some treatment selection on clinical grounds since the 1990s.
  • This finding requires prospective validation, but suggests immune-related gene expression might contribute to IL-2 responsiveness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962351.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Rineer J, Schreiber D, Wortham A, Olsheski M, Sroufe R, Sura S, Katsoulakis E, Han P, Choi K, Rotman M: Utilization of radiation therapy in early-stage Hodgkin disease and its impact on survival. J Clin Oncol; 2009 May 20;27(15_suppl):8511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization of radiation therapy in early-stage Hodgkin disease and its impact on survival.
  • : 8511 Background: Despite numerous randomized trials confirming the benefit of consolidation radiation therapy (RT) in the management of early stage Hodgkin disease (HD), utilization of RT in this setting remains variable.
  • METHODS: The surveillance, epidemiology and end results (SEER) registry was used to identify patients aged 15-75 years diagnosed between 1990-2004 with early stage (stage I-IIA/B) HD, excluding nodular lymphocyte predominant HD.
  • The majority (71.3%) had nodular sclerosis (NS) type HD.
  • By clinical stage, 3399 (34.9%) were stage I, and 6330 (65.1%) were stage II.
  • RT was more likely to be employed during the early era of treatment, in younger patients, females, non-Blacks, and in NS, mixed cellularity and lymphocyte-rich HD.
  • CONCLUSIONS: In this large population-based series of early stage HD patients, the use of RT is associated with a significant OS and CSS benefit across all subgroups.
  • Current efforts in clinical trials have aimed at decreasing the utilization of RT among this patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960874.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Stathis A, Hotte S, Hirte H, Chen EX, Webster S, Iacobucci A, McGill S, Wang L, Espinoza-Delgado I, Siu LL: Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):3528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL).
  • The ideal dose scheduling of these drugs remains controversial.
  • This phase I study aims to determine the recommended phase II dose (RPTD) of the combination, their toxicity profile, pharmacokinetic (PK) interaction and preliminary clinical activity.
  • Dose escalation of D and V on the sequential schedule is described in Table.
  • RESULTS: To date, 27 pts have been entered into dose levels 1, -1, 1a, 1b, -1b, -2b of the sequential schedule.
  • Dose limiting toxicities (DLT) consisted mainly of myelosuppression, constitutional and gastrointestinal symptoms occurred in 7/27 (26%) of pts so far.
  • Disease stabilization for 4 or more cycles was observed in 7 out of 22 (31.8%) evaluable pts (two with breast and one each of thymus, colon, pancreatic, appendix and non-small cell lung cancers).
  • CONCLUSIONS: The sequential combination of D and V seems to be tolerable after some adjustments in the doses and duration of drug administration.
  • Prolonged disease stabilization has been observed in multiple tumor types.
  • Accrual is ongoing and RPTD will likely be dose level -1b or -2b. ( Supported by NCI Grant No. U01CA132123.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961316.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Villano JL, Letarte N, Yu JM, Shakir AR, Bressler L: Hematologic adverse events associated with temozolomide (TMZ). J Clin Oncol; 2009 May 20;27(15_suppl):2053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2053 Background: Secondary acute myeloid leukemia (AML) is reported to occur in 3%-10% of patients treated with alkylating agents for Hodgkin's lymphoma, non-Hodgkin's lymphoma, ovarian cancer, breast cancer, and multiple myeloma.
  • Chemotherapy induced aplastic anemia is usually dose-related versus an idiosyncratic mechanism.
  • Among these patients, we identified 140 cases that we labeled as major hematologic adverse events: agranulocytosis (8 cases), aplasia (42), aplastic anemia (52), leukemia (26), MDS (6), and lymphoma (6).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Flinn IW, Byrd JC, Furman RR, Brown JR, Lin TS, Bello C, Giese NA, Yu AS: Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies.
  • In vitro studies of 0.1 to 10 μM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.
  • METHODS: In an ongoing phase 1 dose escalation study in sequential cohorts of 3 patients with relapsed/refractory CLL or select B-cell non-Hodgkin's lymphoma, CAL-101 is administered orally twice daily for 28 days per cycle.
  • Clinical response is evaluated according to NCI criteria at the end of Cycles 1 and 2 and every 2 cycles thereafter.
  • RESULTS: To date, 6 patients have been treated in the first 2 cohorts at dose levels of 50 mg and 100 mg and the 200 mg cohort is currently enrolling.
  • Two of 6 patients attained partial response and 4 have stable disease.
  • Partial responses were observed after 2 cycles of 50 mg in a patient with mantle cell lymphoma with 6 prior therapies, and after 1 cycle of 100 mg in a patient with follicular lymphoma with 6 prior therapies, including autologous stem cell transplant.
  • Disease specific cohort expansion will occur at the maximally tolerated dose, and patients with AML will be added.
  • CONCLUSIONS: Early results from a phase 1 study of the oral PI3K p110δ inhibitor CAL-101 show that it is well tolerated and has preliminary clinical activity in patients with B-cell malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Popat UR, Saliba R, Hosing C, Khouri I, Alousi AM, Giralt SA, de Lima MJ, Qazilbash MH, Champlin R, Anderlini P: Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation. J Clin Oncol; 2009 May 20;27(15_suppl):e19507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation.
  • : e19507 Background: Age at diagnosis is a poor prognostic factor for overall survival after standard therapy for HD.
  • We sought to evaluate the effect of older age at diagnosis on transplant outcome.
  • PATIENTS AND METHODS: All patients with HD undergoing autologous transplantation with BEAM conditioning (BCNU, Etoposide, Cytarabine, and Melphalan) between January 1996 and December 2007 were included in this study.
  • Seventy two patients (29%) were older than 40 years of age at the time of initial diagnosis.
  • At transplantation, 63 (25%) were in complete remission (CR); 148 (60%) were in partial remission (PR); and 37 (15%) had stable (SD) or progressive disease (PD).
  • The cumulative incidence of non-relapse mortality at 1 year was 1.6%.
  • In univariate analysis, disease status (p<0.001) and number of prior chemotherapy regimens (p=0.007) were the only factors significantly predicting OS.
  • Disease status was the only factor significant (p<0.01) in a multivariate analysis with a hazard ratio of 2.7 (1.1-6.9) and 9.2 (3.4-25) for patients in PR, and SD/PD respectively (CR reference group).
  • Age at diagnosis was not a significant factor (see table ).
  • CONCLUSIONS: High-dose chemotherapy and autologous transplantation abrogate the adverse impact of age at diagnosis in patients with HD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Muslimani A, Spiro T, Chaudhry A, Taylor H, Jaiyesimi I, Elson P, Daw H: Value of International Prognostic Score (IPS) in predicting need for bone marrow biopsy (BMB) in Hodgkin's lymphoma (HL). J Clin Oncol; 2009 May 20;27(15_suppl):e19531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of International Prognostic Score (IPS) in predicting need for bone marrow biopsy (BMB) in Hodgkin's lymphoma (HL).
  • : e19531 Background: BMB is frequently performed during the staging of patients (pts) with HL.
  • The Ann Arbor classification is currently used to detect pts requiring BMB.
  • METHODS: We retrospectively reviewed charts of 1215 histologically proven HL pts from Jan 2000-Dec 2008 at Cleveland Clinic Taussig and Fairview Moll Cancer Centers.
  • BMI by histology was 4% lymphocyte-rich, 5% nodular sclerosis, 20% mixed-cellularity and 21% lymphocyte-depleted.
  • CONCLUSIONS: using an IPS of >3 for predicting BMI in HL doubled the spec associated with Ann Arbor classification with little loss of sen.
  • The implementation of IPS is a practical and reliable tool that will allow physicians to predict BMI in HL pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961027.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Von Drygalski A, Tran TB, Messer K, Pu M, Corringham S, Nelson C, Ball ED, Ball ED: Predictors of survival in patients with metastatic breast cancer (MBC) treated with high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT). J Clin Oncol; 2009 May 20;27(15_suppl):e22086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of survival in patients with metastatic breast cancer (MBC) treated with high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT).
  • Although HD-ASCT has not resulted in improved overall survival (OS), retrospective analyses may identify patients who benefited.
  • We reviewed records of all patients (n=96) in the bone marrow transplant registry at UCSD treated with HD-ASCT for MBC between 1989 and 2000.
  • METHODS: Age, race, stage at diagnosis, histology, estrogen receptor (ER) and menopausal status, body mass index (BMI) in kg/m2, time to transplant and death, sites of metastasis, disease status prior to and after transplant, and days in hospital were extracted.
  • Brookmeyer & Crowley's 95% confidence intervals, Cox models for predictors of a time-to-event variable and Schoenfeld tests for proportional hazard assumptions were applied.
  • RESULTS: Median OS was 5.6 ys (CI 4.1-7.4) after initial diagnosis and 1.7 ys (CI 1.36-2.07) after transplant.
  • OS after HD-ASCT at 12 ys was 8.2% and, although not statistically significant, 18.5% in ER- and 2.6% in ER+ patients, respectively.
  • Stratified by ER status, stage at diagnosis was an independent predictor of OS.
  • Patients with stage I at diagnosis were at lowest risk of death when compared to stage II-IV patients with HRs of 2.7 (II vs I CI 1.4-5.2), 4.6 (III vs I CI 2.1-10) and 17 (IV vs I CI 6.1- 47.8).
  • CONCLUSIONS: The study highlights that ∼10% of patients experience ≥10 ys survival with HD- ASCT.
  • Obesity, late stage at diagnosis, lobular infiltrating histology and visceral metastasis were independent negative predictors of OS.
  • Although survival was influenced by various disease characteristics, obesity was the only significant patient derived factor.
  • These data may be useful stratification tools for future trials employing HD-ASCT as treatment modality in MBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963264.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Powell SF, Dudek AZ: Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma.
  • : e20007 Background: HD IL-2 has been shown to produce durable responses in patients with metastatic melanoma.
  • METHODS: A retrospective analysis was performed all adult patients with Stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at our institution.
  • HD IL-2 was given I.V. every eight hours as a bolus over 15 minutes at a dose of 600,000 IU/kg.
  • A maximum of 14 doses for each course was given.
  • RESULTS: A total of 15 patients with metastatic melanoma had been treated with HD IL-2 at our institution.
  • Complete response (CR) was seen in 6.67% (N=1), partial response (PR) in 6.67% (N=1), mixed response (MR) in 6.67% (N=1), and stable disease (SD) in 13.33% (N=2).
  • Average time to disease progression (TTDP) was 5.67 months in those with a PR or SD.
  • Two patients with brain metastases had subsequently complete resolution of the brain lesions after HD IL-2 therapy.
  • One of these patients has a CR and is disease free 34 months out from therapy.
  • The other had PR and is currently alive with disease, but has no recurrence of the brain lesion after over 19 months.
  • On average patients tolerated 10.5 HD IL-2 doses with the first course and 8.8 doses with the second course.
  • CONCLUSIONS: The CR rate of 6.67% and TTDP in those with SD or a PR are comparable to previously published studies.
  • HD IL-2 has typically been avoided in patients with brain metastases due to concern for neurologic complications from the capillary leak syndrome caused by treatment.
  • We propose further evaluation of this ineligibility for HD IL-2, since carefully selected patients with brain metastases may derive benefit from this treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Hoffman KR: Understanding among medical oncologists of the true monetary cost of therapy. J Clin Oncol; 2009 May 20;27(15_suppl):6629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 50 medical oncologists agreed to take a survey judging their knowledge of the financial cost of the treatments used in patients with the five most common tumors treated in the office: breast cancer, non-small cell lung cancer, colorectal cancer, non-Hodgkin's lymphoma, and three other commonly treated cancers: chronic myelogenous leukemia, multiple myeloma and ovarian cancer.
  • Treatment regimens in the adjuvant and first line metastatic setting were used.
  • They were asked to calculate the cost based a patient completing their adjuvant therapy or treatment in the first-line metastatic setting, which was defined by each practicioner.
  • More education is needed in the economics, including monetary cost-benefit analysis, of oncology practice so that we can better serve our patients and society.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Townsend AR, Millward M, Price T, Mainwaring P, Spencer A, Longenecker A, Palladino MA, Lloyd GK, Spear MA, Padrik P: Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J Clin Oncol; 2009 May 20;27(15_suppl):3582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm).
  • : 3582 Background: The novel structure (non-peptide based) of NPI-0052 (NPI) appears to lead to unique proteasome inhibition (PI), toxicology and signal transduction profiles.
  • Preclinical research suggests improvements in therapeutic ratio and activity in hematologic and solid tumor models, leading to clinical trials in patients with myeloma, lymphomas, leukemias, and solid tumors.
  • METHODS: Patients with solid tumor, lymphoma or leukemia diagnoses without standard treatment options were treated with IV NPI on Days 1, 8 and 15 of 28-day cycles in a 3+3 design dose escalation to a Recommended Phase 2 Dose (RP2D).
  • Enrollment then began in 10 patient lymphoma and CLL RP2D cohorts.
  • RESULTS: 30 patients were treated at doses ranging from 0.1 mg/m<sup>2</sup> to 0.9 mg/m<sup>2</sup>.
  • At the RP2D fatigue, parosmia/dysgeusia, transient peri-infusion site pain and lymphopenia were commonly ascribed to NPI.
  • PI was assayed in blood, indicating a dose:response relationship with mean inhibition of chymotrypsin-like activity up to of 88% Day 1 and 100% Day 15, and inhibition of caspase-like and trypsin-like activity of up to 51% and 72%.
  • PI remained between doses in whole blood (RBC), but recovered between doses in PBMC.
  • Stable disease was induced in 31% of patients, including one each with mantle cell, Hodgkin's lymphoma, follicular lymphoma, sarcoma, prostate carcinoma, and two with melanoma.
  • CONCLUSIONS: NPI-0052 produces dose-dependent pharmacologic effects through the predicted efficacious range to an MTD, while producing a toxicity profile that is tolerable and dissimilar to bortezomib in spite of reaching higher PI levels.
  • These data indicate potential for a greater range of uses than other proteasome inhibitors and lead to additional studies being initiated in hematologic malignancies and solid tumors alone and in combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Sohn B, Yoon D, Kim S, Lee D, Kim S, Huh J, Lee J, Suh C: Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e19543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy.
  • : e19543 Background: The optimal therapy for primary gastric diffuse large B- cell lymphoma (DLBCL) still needs to be defined.
  • METHODS: We searched AMC Registry for Non-Hodgkin's Lymphoma and found 26 patients with primary gastric DLBCL, who received R-CHOP as first-line chemotherapy.
  • Ten of 26 patients had localized disease.
  • Remaining patients had disseminated disease.
  • After analyses of 10 patients with localized disease, we found that these patients had received a total 38 cycles, with a median of 3 cycles per patient.
  • Of 10 patients, one patient had 2 cycles of R-CHOP, 4 had 3 cycles, and one had 4 cycles, all 6 patients above followed by consolidation radiotherapy.
  • Remaining one patient and 4 patients had 5 cycles and 6 cycles of R-CHOP, respectively.
  • In patients with localized disease, CR was observed in 10 of 10 patients (100%), and both 3-year EFS and OS was 100% (10 of 10 patients).
  • In analyses with 16 patients with disseminated disease, all patients had received a total 91 cycles, with a median of 6 cycles per patient.
  • CR after R-CHOP treatment was observed in 10 of 16 patients (62.5%), partial response in 3 patients, stable disease in 1 patient, and progressive disease in 1 patient.
  • Three-year EFS and OS was 61.1% and 57.8% in patients with disseminated disease.
  • Combination with rituximab in CHOP regimen showed excellent prognosis especially in patients with localized disease.
  • In localized disease, CR was 100%, 3-year EFS and OS was 100%.
  • In disseminated disease, CR was 62.5%, 3-year EFS and OS was 61.1% and 57.8%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Matous J, Letzer J, Rosen P, Noga S, Fowler N, Smith S, Amin B, Shi H, Parasuraman S, Cheson B: Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study. J Clin Oncol; 2009 May 20;27(15_suppl):8550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.
  • : 8550 Background: FL is an incurable indolent B-cell non-Hodgkin's lymphoma.
  • Bortezomib (Velcade, V) plus R was active and generally well tolerated in rel/ref FL [de Vos ASH 2006 Abs694], and bendamustine hydrochloride (Treanda, B) plus R has also shown activity in heavily pretreated FL [Robinson JCO 2008].
  • Here we report the safety of dose escalation of B in combination with VR.
  • METHODS: Pts with relapsed FL with ≥4 prior doses of R (no prior V or B), ≥1 measurable tumor mass, no active central nervous system lymphoma, KPS ≥50%, adequate hematologic, renal and hepatic function, and no peripheral neuropathy ≥G2 were eligible.
  • Pts received five 35d cycles of V 1.6 mg/m<sup>2</sup> (d1, 8, 15, 22), B 50, 70, or 90 mg/m<sup>2</sup> (d1, 2) and R 375 mg/m<sup>2</sup> (d1, 8, 15, 22, cycle 1; d1, cycles 2-5).
  • B dose escalation continued based on cycle 1 dose-limiting toxicities (DLTs), defined as: treatment-related platelet count <25,000/mm<sup>3</sup> for >7 days or any platelet count <10,000/mm<sup>3</sup>; G4 neutropenia for >7 days; any treatment-related ≥G3 non-hematologic toxicity other than inadequately treated nausea, vomiting, or diarrhea; or any toxicity resulting in >1 week treatment delay.
  • Non-hematologic AEs ≥G3 in >1 pt were diarrhea (31%), fatigue (25%), vomiting (13%), and nausea (13%).
  • CONCLUSIONS: Enrollment is continuing in the phase II portion of the study with B 90 mg/m<sup>2</sup>, the highest planned dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960956.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Timmerman J, Betting D, Yamada R, Hurvitz S, Steward K, Said J, van Rooijen N, Kafi K: In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma.
  • : 8529 Background: The anti-CD20 monoclonal antibody rituximab (R) is a mainstay in the treatment of B cell non-Hodgkin's lymphoma (NHL), exerting anti-tumor effects via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, and apoptosis induction.
  • Toll-like receptor 9 agonist CpG oligodeoxynucleotides (CpG) are potent activators of ADCC and T cell immunity, and have been studied for anti-NHL effects when administered by systemic or intratumoral routes.
  • METHODS: We utilized an aggressive syngeneic human CD20-expressing murine B cell lymphoma (38C13-huCD20) to study the in vivo augmentation of R efficacy by CpG.
  • Combining intratumoral, but not systemic administration of CpG with R resulted in tumor eradication from up to 42% of mice (p < 0.0003 vs. R alone, CpG alone, R + systemic CpG).
  • In contrast, equivalent doses of unlinked i.v.
  • CONCLUSIONS: In conclusion, enhancement of R efficacy required sustained intratumoral delivery of CpG to maximize anti-tumor responses.
  • R-CpG conjugate efficiently eradicated an established B cell lymphoma that is fully resistant to single-agent R.
  • Clinical testing of anti-CD20-CpG conjugates against B cell NHL is thus warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Cheson BD, Vose JM, Bartlett NL, Lopez A, Van der Jagt RH, Tolcher AW, Weisenburger DD, Seiz AL, Shamsili S, Keating AT: Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol; 2009 May 20;27(15_suppl):8502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL).
  • YM155, a survivin suppressant, has exhibited anti-tumor activity in solid tumors and non-Hodgkins lymphoma (NHL), including DLBCL patients enrolled in Phase I and Phase II monotherapy studies.
  • Patients could continue to receive YM155 until disease progression or unacceptable toxicity.
  • Three patients (11%) had partial responses (PR) confirmed by independent review using Cheson criteria (N=2; 1999 criteria and N=1; 2007 updated criteria).
  • One patient responded after 2 cycles, completed 5 total cycles and proceeded to SCT (disease-free > 3.7 years post SCT).
  • The third patient responded after 12 cycles and received 26 total cycles (1.5 years) before disease progression.
  • Because of single-agent activity and preliminary data showing synergism when YM155 is combined with other agents additional clinical studies are being planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Amireault C, Camden S, Poulin J, Lemieux J: Evaluation of factors associated with recruitment in hematological clinical trials: A retrospective study. J Clin Oncol; 2009 May 20;27(15_suppl):6567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of factors associated with recruitment in hematological clinical trials: A retrospective study.
  • : 6567 Background: Recruitment of patients in cancer clinical trials has been reported to be between 3%-5%.
  • METHODS: The objective was to measure the recruitment and its associated characteristics in hematology clinical trials for malignant diseases.
  • Clinical trials opened between 2002 and 2008 were selected.
  • For each protocol, main criteria were used to define the population under study (e.g., stage IV Hodgkin lymphomas first-line).
  • The study population filling the main criteria of a protocol included 195 observations in 17 protocols (186 different patients).
  • However, theses rates reached 68.2 % (61.2-75.1) and 23.1 % (17.9-29.8), respectively, among patients meeting the main criteria of a protocol (195 observations).
  • Patients reasons for refusals were (could have more than one reason): 50% unknown, 26.5% fear of side effects, 20.6% too many visits, 14.7 % already enough anxious about disease, other.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Vrettos I, Papadopoulos A, Kamposioras K, Charitos D, Giannopoulos G, Pectasides D, Niakas D, Economopoulos T: Corrleation of health-related quality of life (HRQL) of cancer patients and the mental component parameters of their family members. J Clin Oncol; 2009 May 20;27(15_suppl):e20619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, physical functioning (PF), role physical (RP), bodily pain (BP), general health perception (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH) of the patients were correlated with the SF, RE, MH of their family members using the Spearman's test.
  • CONCLUSIONS: HRQL of cancer patients undergoing chemotherapy is highly correlated with the SF and the MH of their relatives.
  • ABBREVIATIONS: PF = Physical Functioning, RP = Role Physical, BP = Bodily Pain, GH = General Health, VT = Vitality, SF = Social Functioning, RE = Role Emotional, MH = Mental Health; NS=Not Significant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961615.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Oatis WS, Nonzee N, Markossian T, Shankaran V, McKoy J, Evens A, Gordon L, Winter J, Calhoun E, Bennett CL: Interpreting out-of-pocket expenditures for cancer patients: The importance of considering baseline household income information. J Clin Oncol; 2009 May 20;27(15_suppl):6541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report income-adjusted out-of-pocket cost ratios for 50 patients with lymphoma and 156 patients with breast cancer.
  • METHODS: Patients with lymphoma or breast cancer provided 3-month retrospective documentation of cancer-related out-of-pocket costs.
  • Direct non-medical costs are cancer-related peripheral costs, such as transportation and meals.
  • Mean monthly out-of-pocket costs for patients with lymphoma were slightly greater than for those with breast cancer ($1,888 vs $1,455, respectively).
  • Among patients with an annual income of $30,000 or less, the total monthly out-of-pocket costs were more than 3 times the monthly household income for patients with lymphoma and equal to the monthly household income for patients with breast cancer.
  • The total mean income-adjusted cost ratio was 1.75 for patients with aggressive non-Hodgkin lymphoma versus 0.42 and 0.61 for those with indolent non-Hodgkin lymphoma or Hodgkin disease, respectively.
  • CONCLUSIONS: Cancer-related out-of-pocket expenses disproportionately affect lower-income individuals with lymphoma or breast cancer and are primarily driven by the financial burden of co-payments for medical care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964057.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Ghavamzadeh A, Allahyari A, Alimoghaddam K, Karimi A, Shamshiri A, Abolhasani R, Manookian A, Asadi M, Khatami F: Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders.
  • : 7042 Background: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including Hodgkin/non-Hodgkins lymphoma and acute leukemias.
  • METHODS: 9 outpatients (5 HL, 2 NHL, and 2 AML) were compared with 32 inpatients (15 HL, 8 NHL, and 9 AML; for whom the outpatient facilities were not ready) from May 2008 to December 2008.
  • They received conditioning regimen (CEAM for NHL and HL, busulfan and etoposide for AML) and stem cell infusion in hospital.
  • The day after SCT, outpatient group were discharged and followed by outpatient SCT team, and to be re-hospitalized in case of febrile neutropenia, after sepsis workup and performing chest x-ray, they were received the first dose of antibiotic in hospital and treatment continued in home.
  • CONCLUSIONS: Results show that out-patient autologous SCT in malignant hematologic disorders is feasible and comparable with inpatient protocol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. O'Brien MM, Donaldson SS, Whittemore AS, Link MP: Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):10003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy.
  • : 10003 Background: Second malignant neoplasms (SMN) are a known complication of Hodgkin disease (HD) treatment.
  • While it is theorized that lower radiation doses may be associated with lower SMN risk, long-term follow-up of children treated with low-dose radiation is lacking.
  • We report the occurrence of SMN among pediatric HD survivors treated at Stanford with chemotherapy and low-dose radiation from 1970 to 1990.
  • Fifteen patients developed 17 secondary solid tumors (5 thyroid carcinomas, 6 breast carcinomas, 4 sarcomas, 1 bladder paraganglioma, 1 melanoma) at a median of 15.4 years.
  • All solid tumors except the melanoma occurred within or at the margin of radiation fields, ranging in dose from 15-26.5 Gy.
  • Cumulative incidence of any SMN is 17% (95%CI 10.5-26.7) at 20 years following HD diagnosis.
  • In univariate analysis, older age at HD diagnosis (>11 years) and female gender were associated with SMN (p<0.05).
  • CONCLUSIONS: The incidence of SMN in pediatric HD survivors is elevated following treatment with chemotherapy and low-dose radiation.
  • Sarcomas, breast, and thyroid carcinomas occurred with similar frequency and latency as found in studies of HD survivors who received high-dose radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962547.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Corazzelli G, Frigeri F, Marcacci G, Capobianco G, Arcamone M, Becchimanzi C, Russo F, Pinto A: Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma.
  • : 8579 Background: Gemcitabine (G), ifosfamide (Ifo), oxaliplatin (Ox) and rituximab (R) have been accounted of cross-synergy in preclinical and early clinical studies in Hodgkin lymphoma (HL).
  • We assessed activity, toxicity and stem cells (SCs) mobilizing capacity of a bi-weekly salvage combination with these agents in HL recurring after conventional or high dose therapy (HDT).
  • R-GIFOX consisted of R 375 mg/m<sup>2</sup> D1, G 1000 mg/m<sup>2</sup> D2, Ox 130 mg/m<sup>2</sup> D3 and Ifo 5 g/m<sup>2</sup> D3, as a 24-h single infusion, G-CSF 5 mcg/kg/d DD 7-11 (10 mcg/kg/d, 3rd course until SCs mobilization).
  • RESULTS: Twenty-one patients (median age 33 yrs, r 22-64) with relapsed (n = 16) [post-ASCT (n=6), <12 mo.s (n=7), > 12 mo.s (n=3)] or primary progressive (n = 5) HL, were prospectively accrued.
  • Ten patients (48%) had received ≥ 2 previous CHT lines and 15 (78%) had GHLSG recurring HL prognostic score ≥ 2.
  • Actual dose intensity of the first 3 courses was 82%, 86%, 92 % for G, Ifo and Ox, respectively.
  • At a median f.u. of 12 mo.s for CRs, Disease Free Survival was 79% in patients eligible for ASCT and 41% in those unfit treated with additional R-GIFOX.
  • CONCLUSIONS: R-GIFOX retains an attractive therapeutic potential in recurring HL, enabling pre-ABMT cytoreduction and mobilization, and also a safe delivery of a full salvage program to patients unfit for HDT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Ma CX, Lin L, Gao F, Giuntoli T, Chia YH, Guo Z, McDowell R, Naughton M, Watson M, Ellis M: PIK3CA mutation analysis in recurrent breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11041 Background: Mutations in PIK3CA (encoding p110α catalytic subunit of phosphatidylinositol-3-kinase) are among the most common genetic events identified in breast cancer but the role of these mutations in determining the clinical course of the disease is uncertain.
  • In this study, we performed a mutational analysis of exons 9 (HD) and 20 (KD) of the PIK3CA using tumor DNA obtained from pts with recurrent disease and correlated mutational status with clinicopathological features and prognosis.
  • RESULTS: Biopsies were obtained from sites of recurrence in 51 pts with stage 4 disease.
  • Mutations in PIK3CA were identified in 24.5% (11.3% in HD and 13.2% in KD).
  • PIK3CA mutation was significantly correlated with lower tumor grade (47% in grade 1/2 vs 8% in grade 3, p=0.004), positive ER (35% in ER+ vs 5% in ER-, p=0.017), and PR (37% in PR+ vs 5% in PR-, p=0.011).
  • Overall survival (OS) was 139.5 and 53.7 months for mutation- and non-mutation- carriers respectively (p=0.014).
  • CONCLUSIONS: About one quarter of pts with recurrent/advanced breast cancer carry PIK3CA mutations in samples of recurrent disease, which correlated with positive ER/PR status and a more indolent clinical course.
  • These patients are good candidates for experimental protocols that combine endocrine agents with PI3 kinase inhibitors but the slower kinetics of disease progression in PIK3CA mutation carriers may have to be taken into account for statistical designs and power size calculations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963981.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Cadoo KA, Lowery MA, Cumiskey J, McCaffrey J, Carney DN: Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract. J Clin Oncol; 2009 May 20;27(15_suppl):e19516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract.
  • : e19516 Background: Anthracycline based chemotherapy is the treatment of choice for aggressive primary lymphomas of the GI tract, with surgery reserved for management of complications.
  • Median age at diagnosis was 60 (15-83).
  • Of the aggressive lymphomas (63), all patients with T cell lymphoma had small bowel as primary site and histological evidence of celiac associated enteropathy, even in the absence of known celiac disease.
  • 39 (62%) patients underwent surgery at diagnosis due to acute presentation with perforation, bleeding or obstruction, or to obtain histology.
  • Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.
  • 2 patients with T cell lymphoma presented with perforation, were treated with surgery only and died of rapid disease progression.
  • Of the 63 patients with aggressive NHL, 37 (59%) remain alive & disease free at median follow up of 13 years (1-24).
  • 35 (67%) patients with DLBCL are alive & disease free.
  • Only 2 (18%) of the T cell lymphomas are alive & disease free.
  • All deaths in the T cell group were due to progressive disease.
  • However, in contrast, coeliac enteropathy associated T-cell lymphomas present with rapidly progressive disease & have a survival of < 20% with chemotherapy and/or surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Arias-Mendoza F, Leach MO, Koutcher JA, Griffiths JR, Heerschap A, Glickson JD, O'Connor OA, Brown TR, Cooperative Group for MR Applications in Cancer: Prediction of treatment response in subtypes of non-Hodgkin's lymphoma by in vivo &lt;sup&gt;31&lt;/sup&gt;P MR spectroscopy before treatment. J Clin Oncol; 2009 May 20;27(15_suppl):8565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of treatment response in subtypes of non-Hodgkin's lymphoma by in vivo <sup>31</sup>P MR spectroscopy before treatment.
  • : 8565 Background: To determine if the intracellular tumor marker of phosphoethanolamine plus phosphocholine normalized by nucleotide triphosphates (PPN) monitored non-invasively by phosphorus MR spectroscopy (<sup>31</sup>P-MRS) correlate with indicators of treatment response in non-Hodgkin's lymphoma (NHL) subtypes.
  • METHODS: The PPN value was obtained in 33 diffuse large B-cell lymphomas (DLBCL), 18 follicular lymphomas (FL) and 16 other types (OT) of NHL using in vivo 3D-localized, <sup>1</sup>H-irradiated <sup>31</sup>P-MRS prior to standard treatment.
  • Further, when the PPN was combined with the international prognostic index (IPI) to predict treatment response, the Fisher test increased significance (p<0.0002; sensitivity and specificity=0.9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961022.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement